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Abstract 
OS-9 Regulates Hypoxia-Inducible Factor 1 in the Endoplasmic Reticulum 
Taotao Lao 
Nianli Sang, Ph.D. 
 
Hypoxia-inducible factor 1HIF-1) is the master regulator of oxygen homeostasis and 
plays critical roles in cells’ responses to multiple signaling by activating 
proangiogenic progress and adaptive metabolism. This critical transcription factor is 
also involved in pathologic processes such as erythrocytosis, inflammation, and tumor 
progression. Therefore, understanding HIF-1 regulation will provide better strategies 
for management of diseases. HIF-1 is an  heterodimer and its regulation is mainly 
through post-translational regulation of HIF-1. Oxygen-dependent hydroxylation-
ubiquitination-proteasomal degradation of HIF-1 represents the canonical 
mechanism underlying oxygen sensing. Ubiquitination-independent degradation (UIP) 
induced by cancer chemotherapeutics also has been observed, but its mechanism is 
still unknown. TS20 cells have been used in studying UIP due to the instability of the 
ubiquitin activating enzyme E1 at the restrictive temperature. In the first part of this 
study, we have investigated the molecular basis of the temperature sensitive 
phenotype of the TS20 cells. We demonstrate that there are two point mutations on 
E1 protein that cause the instability of E1 protein under restrictive temperature which 
further leads to the inhibition of the ubiquitination process. This study validates an 
essential model cell line to study the ubitination-dependent and –independent 
degradation of proteins.  OS-9, which has been found as an HIF-1 partner that 
regulates HIF-1 stability, is a component of endoplasmic reticulum (ER)-associated 
xiii 
 
protein control system which removes misfolded glycoproteins in the ER-associated 
degradation (ERAD) pathway. In the second part of this study, we demonstrate that 
HIF-1 is under the surveillance of the ER associated protein quality control system 
where OS-9 directly interacts with HIF-1in ER-derived vesicles and promotes its 
degradation by the proteasome. These findings indicate a novel mechanism that 
regulates HIF-1 stability and suggests that the ER protein quality control system 
appears to participate in the surveillance of nuclear proteins. Tunicamycin, an 
antibiotic that inhibits N-linked glycosylation, is also an ER-stress inducer. In the 3
rd
 
part of this study we that tunicaymcin decreases HIF-1 levels and functions by a 
mechanism that is independent of ubiquitination system. We further demonstrate that 
hypoxia induced doxorubicin resistance in renal carcinoma cells is reduced by 
tunicamycin treatment, indicating that tunicamycin may serve as a HIF-1 inhibitor 
that sensitizes cells to tumor therapy by inhibition of hypoxic adaptation in tumor 
cells.  Taken together, our data indicate that an OS-9 participated ER function is 
involved in the UIP degradation of HIF-1 which may form part of the quality 
control system of HIF-1. 
 
 
1 
 
 
 
 
Chapter1: Background 
Hypoxia and HIFs 
Molecular oxygen (O2) is essential for all aerobic organisms by providing oxidative 
power for energy supply in mitochondria as well as being involved in a large number of 
enzymatic reactions in the cell. Excess oxygen supply (hyperoxia) can produce reactive 
oxygen species, such as superoxide ion (O2
-
) and hydrogen peroxide (H2O2) which can 
lead to oxygen toxicity. Inadequate oxygen supply, also known as hypoxia, is critical for 
many physiological and pathophysiological processes (Semenza, Agani et al. 2000). 
Therefore, accurate regulation of oxygen homeostasis is essential for survival. 
Multicellular organisms have evolved tightly regulated mechanisms to maintain oxygen 
homeostasis by oxygen sensing, signal transduction and effectuation at cellular, local and 
systemic levels (Bunn and Poyton 1996).   
Hypoxia inducible factors (HIFs) are transcriptional factors regulating hypoxic adaptation 
of cells and are conserved during evolution from worms to vertebrates and play a central 
role in oxygen homeostasis during embryonic development and postnatal life that link 
between oxygen sensors and effectors at both cellular and systemic levels (Wang, Jiang et 
al. 1995; Wang and Semenza 1995; Semenza 2002). Under hypoxia condition, HIFs 
activate a large group of hypoxia-inducible genes which promote survival in low-oxygen 
conditions (Semenza 2002). These include glycolysis enzymes, which allow ATP 
synthesis in an oxygen-independent manner, and vascular endothelial growth factor 
(VEGF), which promotes angiogenesis. HIFs are also involved in pathologic processes 
such as erythrocytosis, inflammation, and tumor development, angiogenesis, and 
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metastases (Ema, Taya et al. 1997; Maxwell, Pugh et al. 2001; Semenza 2001; Harris 
2002). 
HIFs are heterodimers formed by HIF- and HIF- subunits (also known as the aryl 
hydrocarbon nuclear receptor translocator, ARNT) (Wang, Jiang et al. 1995; Wang and 
Semenza 1995). The alpha subunit is highly oxygen sensitive and is stabilized in hypoxia 
condition, whereas the beta subunit is oxygen insensitive and is constitutively expressed 
in the nuclear serving as the DNA-binding partner for the alpha subunit. So the oxygen 
dependent regulation of HIFs functions is primarily mediated through the HIF- subunit. 
Both HIF- and HIF- subunits share a similar domain at the N-terminal, namely the 
basic helix-loop-helix (bHLH) and PER-ARNT-SIM (PAS) which mediates dimerization 
and is essential for HIF transcriptional activity (Lindebro, Poellinger et al. 1995; Pongratz, 
Antonsson et al. 1998) (Fig.1-1A). 
Among the three HIF family members, HIF-1 is ubiquitously expressed, while HIF-2 and 
HIF-3 are expressed in a more tissue specific manner (Ema, Taya et al. 1997; Flamme, 
Frohlich et al. 1997; Tian, McKnight et al. 1997; Gu, Moran et al. 1998).  Unlike HIF-1 
and HIF-2, which activate hypoxia induced gene expression in response to low oxygen 
condition, IPAS, a splice variant form of HIF-3, due to the lack of transcriptional 
activation domain, serves as a HIF antagonist that represses hypoxic regulated gene 
expression (Makino, Cao et al. 2001).  
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Oxygen-dependent repression of HIF-1 
The regulation of HIF-1 function is controlled by its alpha subunit. Under normoxic 
conditions, although HIF-1 mRNA is continuously translating, newly synthesized HIF-
1 protein is rapidly degraded by the ubiquitination-proteasomal system (Huang, Arany 
et al. 1996; Salceda and Caro 1997; Kallio, Wilson et al. 1999). This degradation is 
mediated through sequential post-translational modifications of HIF-1. With sufficient 
oxygen supply, two prolyl residues (P402 and P564) in the oxygen-dependent 
degradation domain (ODD) of HIF-1 are hydroxylated by a family of proline 
hydroxylases (PHD1, PHD2, and PHD3) (Pugh, O'Rourke et al. 1997; Huang, Gu et al. 
1998; Srinivas, Zhang et al. 1999; Ivan, Kondo et al. 2001; Jaakkola, Mole et al. 2001; 
Masson, Willam et al. 2001; Yu, White et al. 2001). This reaction requires O2, 2-
oxoglutarate, Fe
2+
 and ascorbate, making PHD (1-3) the oxygen-sensing component of 
the HIF system (Bruick and McKnight 2001; Epstein, Gleadle et al. 2001). The hydroxyl 
modified HIF-1 is further recognized and ubiquitylated by an E3 ubiquitin ligase 
complex containing the von Hippel-Lindau tumor suppressor protein for degradation by 
the 26 S proteasome (Salceda and Caro 1997; Huang, Gu et al. 1998). Due to the high 
efficiency of the hydroxylation as well as the subsequent degradation reactions, HIF-1 
is rapidly degraded within 5 min.    
Under hypoxia condition, PHD activity is inhibited by limited oxygen concentration, thus 
the HIF-1 prolyl residues remain unmodified. The interaction between HIF-1 and 
VHL associated E3 ubiquitin ligase complex is abolished, which stabilizes the HIF-1 
protein (Bruick and McKnight 2001; Epstein, Gleadle et al. 2001; Ivan, Kondo et al. 2001; 
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Jaakkola, Mole et al. 2001). Another level of regulation is through activating HIF-1 
transactivation activity. HIF-1 has two transactivation domains, an N-terminal and a C-
terminal transactivation domain (NAD and CAD, respectively) (Jiang, Agani et al. 1997; 
Pugh, O'Rourke et al. 1997; O'Rourke, Tian et al. 1999). HIF-1 CAD provides the 
major transactivation activity which is achieved by post-translational modifications of the 
domain to recruit the co-activator p300/CBP through hydrophobic and stereostatic 
interaction (Arany, Huang et al. 1996; Bhattacharya, Michels et al. 1999; Dames, 
Martinez-Yamout et al. 2002; Freedman, Sun et al. 2002; Sang, Fang et al. 2002). These 
modifications are mediated by an oxygen-dependent asparaginyl hydroxylase, the protein 
factor inhibiting HIF-1 (FIH), which hydroxylates the asparagines residue at Asn803 of 
HIF-1 under normoxia conditions. This modification represses HIF-1 transactivation 
activity by inhibiting the interaction of HIF-1 CAD with p300/CBP (Fig.1-1B) (Mahon, 
Hirota et al. 2001; Lando, Peet et al. 2002; Sang, Fang et al. 2002).  
Oxygen-independent regulation of HIF-1 
In addition to the O2-dependent regulation pathways, HIF-1 stability is also regulated 
by O2-independent pathways. HIF-1 protein is posttranslationally modified by 
nitrosylation, phosphorylation, acetylation, carboxylation and sumoylation, and these 
modifications can affect protein folding, localization, stability and transactivation activity 
(Bardos and Ashcroft 2005). One of these oxygen-independent pathways involves 
HSP70/HSP90 chaperone machinery which is essential in protein folding and quality 
control in the cell by aiding newly translated protein folding or leading to the degradation 
of misfolded and destabilized proteins (Hutchison, Dittmar et al. 1994). This machinery 
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is ubiquitously found in all eukaryotes, and its client proteins can be classified into two 
classes: transcription factors and signaling kinases. Both HSP70 and HSP90 have been 
found to interact with HIF-1(Isaacs, Jung et al. 2002; Mabjeesh, Post et al. 2002; Kong, 
Lin et al. 2006; Luo, Zhong et al. 2010). HSP70 recruits the chaperone-dependent E3 
ubiquitin ligase, CHIP, which facilitates HIF-1 degradation (Luo, Zhong et al. 2010). 
Inhibition of HSP90 activity with geldanamycin and 17-allylaminogeldanamycin (17-
AAG) increases HIF-1 ubiquitination and degradation (van de Sluis, Groot et al. 2009) 
(Fig.1-1B). 
Subcellular compartmentalization and HIF regulation 
Besides regulating HIF-1 by affecting its stability and transactivating activity, 
subcellular compartmentalizatin of HIF-1 and its partner proteins can also contribute to 
the overall regulation. In the primary structure of HIF-1 protein, there is a nuclear 
localization signal (NLS) localized at C-terminal amino acids 718-721 which plays a 
critical role in the hypoxia-induced nuclear translocation by the importin  or importin 
4/7 system (Kallio, Okamoto et al. 1998; Depping, Steinhoff et al. 2008; Chachami, 
Paraskeva et al. 2009). HIF-1 also contains a nuclear export signal (NES) localized at 
amino acids 616-658, which recruits nuclear export protein, chromosome region 
maintenance 1 (CRM1) for translocation of HIF-1 out of the nucleus (Romero, Irisarri 
et al. 2008). Under hypoxia condition, HIF-1 translocates to the nucleus to form a 
heterodimer structure with ARNT (HIF-1) (Kallio, Okamoto et al. 1998). Different 
subcellular distribution patterns of HIF-1 have been observed in different cell types 
under different conditions (Normoxia and Hypoxia), and the fact that HIF-1 can be 
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shuttled between the cytoplasm and nucleus in some cells even under hypoxia suggests 
that multiple factors and pathways are dynamically involved in the regulation of HIF-1 
(Kallio, Okamoto et al. 1998; Chilov, Camenisch et al. 1999; Groulx and Lee 2002; 
Zheng, Ruas et al. 2006; Moroz, Carlin et al. 2009).  
The subcellular compartmentalizatin of HIF-1 partner proteins can also contribute to the 
overall regulation. Among the different HIF-1 hydroxylases, PHD2, the main regulator 
of normoxic HIF-1 protein degradation, is localized predominantly in the cytoplasm, 
with some associated with endoplasmic reticulum, mitochondria and additional fraction 
in nucleus (Metzen, Berchner-Pfannschmidt et al. 2003; Barth, Edlich et al. 2009). PHD1 
localizes exclusively in the nucleus and PHD3 in both cytoplasm and nucleus (Metzen, 
Berchner-Pfannschmidt et al. 2003). The VHL, which interacted with hydroxylated HIF-
1 for unbiquitylation, has two forms, VHL30 and VHL19, located mainly in cytoplasm 
and nucleus, respectively (Iliopoulos, Ohh et al. 1998).  Moreover, ubiquitylation or 
SMOylation of VHL protein can affect its stability as well as nucleo-cytoplasmic 
shuttling. This subcellular trafficking and dynamic properties of VHL promote HIF-1 
regulation (Groulx and Lee 2002; Fabbro and Henderson 2003; Cai and Robertson 2010). 
Thus, the regulation of HIF-1 can be mediated by different factors at different 
subcellular localizations. 
Protein quality control system (PQCS) 
Eukaryotic cells have evolved protein quality control systems to detect, repair and 
degrade aberrant proteins, which can arise from mutation, environmental stress, incorrect 
folding, transcriptional or translational errors, imbalanced subunit synthesis, and 
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improper modification and trafficking (Bukau, Weissman et al. 2006; Hartl and Hayer-
Hartl 2009). Persistent exposure to aberrant proteins often results in deleterious 
consequences. For example, various diseases such as Alzheimer's, Huntinton's, 
Creutzfeld-Jakob's and Parkinson's are all linked to the accumulation of aberrant proteins 
and defects in protein quality control (Roth, Yam et al. 2008).  
PQCSs recognize and attempt to fix aberrant proteins by chaperones and co-chaperons. 
For example, Hsp70 (Grp78/Bip/Kar2) and Hsp90 (GRP94) plays a role in protein re-
folding; Hsp40 and its co-chaperones prevent aggregates; and Hsp104 disrupts aggregates 
(Earl, Moss et al. 1991; Chang, Rose et al. 1993; Li and Srivastava 1993; Vacher, Garcia-
Oroz et al. 2005; Lo Bianco, Shorter et al. 2008; Vos, Hageman et al. 2008; Kampinga, 
Hageman et al. 2009; Ye and Li 2009). Since not all aberrant proteins can be repaired, 
un-repaired proteins are degraded either by the ubiquitin proteasomal degradation 
pathway or through the lysosomal pathway (Korolchuk, Menzies et al. 2010; 
Ciechanover 2011) (Figure 1-2). 
The endoplasmic reticulum PQCS machinery has been well defined for secreted and 
membrane bond proteins. ER is the place that most secreted proteins and membrane 
proteins are initially synthesized. Nascent polypeptides containing an N-terminal signal 
peptide are transport into the ER lumen by the Sec61 translocon complex (Klappa, 
Zimmermann et al. 1994; Oliver, Jungnickel et al. 1995; Wiertz, Tortorella et al. 1996; 
Kalies, Rapoport et al. 1998). Those polypeptides containing Asn-X-Ser/Thr motif are 
cotranslationally modified with N-linked glycans and then undergo a series 
lectin/chaperone mediated folding by calnexin, calreticulin, Bip, PDI and/or Grp94 
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containing chaperone complexes (Trombetta and Helenius 1998; High, Lecomte et al. 
2000). Unfolded glycoproteins may be subjected to removal by other lectins such as 
EDEM, XTP3-B and OS-9, which facilitate the retrotransolation of these substrates to the 
cytosol for ubiquitination and degradation by the 26S proteasome (Christianson, Shaler et 
al. 2008; Hosokawa, Kamiya et al. 2009; Bernasconi, Galli et al. 2010; Hosokawa, 
Kamiya et al. 2010)(Figure 1-3).  
In addition to the ER, PQCSs are also present in other subcellular compartments where 
polypeptides are synthesized and matured, such as in the cytosol and mitochondria 
(Tatsuta 2009; Buchberger, Bukau et al. 2010). Although some ubiqutin E3s, such as 
San1 in the budding yeast Saccharomyces cerevisiae specifically targeting aberrant 
nuclear proteins, may function in PQCS machinery, the nuclear PQCS machinery in 
general has still remained elusive (Gardner, Nelson et al. 2005). Since the nuclear 
membrane is the continuous of the rough-ER and there is evidence suggest that different 
quality control pathway may overlap between nucleus and ER/cytosol, unfolded nuclear 
proteins could be under the surveillance of the cytosolic PQCS machinery or ER PQCS 
machinery residing in the inner nuclear membranes (Scharf, Rockel et al. 2007; von 
Mikecz, Chen et al. 2008; Prasad, Kawaguchi et al. 2010; Fredrickson, Rosenbaum et al. 
2011; Matsuo, Kishimoto et al. 2011). 
OS-9  
Human OS-9 gene was first identified in osteosarcomas on 12q13-15, a region frequently 
amplified in human cancers (Su, Hutter et al. 1996; Kimura, Nakazawa et al. 1997). Its 
full-length cDNA sequence encodes an acidic polypeptide with 667 amino-acid residues 
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representing isoform 1 (Su, Hutter et al. 1996). Two additional isoforms of OS-9 cDNA 
were found in myeloid leukemia HL-60 cells with alternative splicing, whereas OS-9.2 
lacked a 165 nucleotide sequence in the coding region expressed predominantly in many 
cancer cells. OS-9.3 which had an additional 45 bp deletion in the coding region was 
rarely detectable (Kimura, Nakazawa et al. 1998).  Both isoform-1 and 2 are expressed in 
all human tissues, however, their expression levels decreased in differentiation-induced 
HL-60 cells (Kimura, Nakazawa et al. 1998) (Figure 1-4).  
The initial functional studies suggested that OS-9 interacted with N-copine, a brain-
specific member of the copine family that may serve as a cytoplasmic Ca
2+
 sensor in the 
synapitic plasticity in a Ca
2+
-dependent manner (Nakayama, Yaoi et al. 1999).  Os-9 was 
also identified interacting with the carboxyl-terminal tail of meprin beta, a membrane 
metalloendoproteinase of the astacin family that plays important roles in inflammation by 
activating cytokines and tumor growth factor (Litovchick, Friedmann et al. 2002). In 
2005, Gregg Semenza’s group reported that OS-9 interacts with both HIF-1 and HIF-
1 prolyl hydroxylases (PHDs), which promoted HIF-1 degradation in an O2-
dependent manner (Baek, Mahon et al. 2005). Recently, the interaction between PHDs 
and OS-9 was challenged by Eric Metzen’s group where no significant physical 
interaction of OS-9 with PHD2 was observed in protein interaction analysis by 
fluorescence resonance energy transfer (FRET) (Brockmeier, Platzek et al. 2011).  
Despite of those sporadic and divergent reports about the function of OS-9, more and 
more studies have merged to point the functions of OS-9 as a component of ER-
associated protein quality control system.  OS-9 was found that preferably interacts with 
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immature TRPV4, a member of a family of cation-permeable channels, and impedes its 
release from the ER to the plasma membrane (Wang, Fu et al. 2007). OS-9 was also 
identified as an ER-lumen protein that does not associate with native proteins but binds 
with mis-folded proteins and prevents them from transporting through the secretory 
pathway as well as promotes these mis-folded proteins disposal from the ER lumen 
(Bernasconi, Pertel et al. 2008). Degradation of other ERAD substrates such as mutant 
alpha-antitrypsin requires the OS-9 associated ER chaperone GRP94 together with the 
ER-membrane-embedded ubiquitin ligase Hrd1 and the SEL1L adaptor suggesting that 
OS-9, as a component of protein quality control system that is involving in protein 
folding, membrane dislocation and ubiquitination (Christianson, Shaler et al. 2008).  
Proteins recognized by the ERAD pathway are polyubiquitinated and retrotranslocated 
into the cytosol for degradation by the proteasome. Although OS-9 binds to both 
misfolded glycosylated protein and nonglycosylated protein for ERAD, however, OS-9 is 
only required for glycosylated protein ubquitination but not for these nonglycosylated 
proteins (Alcock and Swanton 2009; Hosokawa, Kamiya et al. 2009; Mikami, 
Yamaguchi et al. 2010; Satoh, Chen et al. 2010). A sophisticated investigation of ER 
quality control mechanisms revealed that both ERAD lectins, OS-9 and XTP-3B, are 
specifically targeting those soluble (nontransmembrane) polypeptides with luminal 
lesions to the degradation pathway (Bernasconi, Galli et al. 2010). 
Summary 
Although OS-9-HIF-1 interaction was the first reported to take place in the nuclei and 
to be part of oxygen sensing machinery, following up studies clearly indicate that OS-9 is 
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an ER protein. We have also independently identified the interaction between OS-9 and 
HIF-1 in a yeast two-hybrid system. Based on the current findings, we propose a 
hypothesis that OS-9 is involved in quality control of Hypoxia-Inducible Factor 1 in 
the ER.  
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Figure 1-1 
 
Fig.1-1. (A) Schematic structures of HIF-1 (B) HIF-1 regulation by Oxygen-
Dependent Hydroxylation. With sufficient oxygen supply, two prolyl residues (P402 and 
P564) in the ODD domain of HIF-1 are hydroxylated by proline hydroxylases 
(PHDs).The hydroxylation modified HIF-1 is further recognized and ubiquitylated by a 
VHL E3 ubiquitin ligase complex for degradation by the 26 S proteasome. Another level 
of regulation is through activating HIF-1 transactivation activity. The protein factor 
inhibiting HIF-1 (FIH), which hydroxylates the asparagines residue at Asn803 of HIF-
1 under normoxia conditions that represses the HIF-1 transactivation activity by 
inhibition the interaction of HIF-1a CAD with p300/CBP. 
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Figure 1-2 
 
Figure 1-2: Protein quality control System. 
 
 
 
 
 
 
 
14 
 
 
 
 
Figure 1-3 
 
Figure 1-3: ER-Associated Protein quality control System. 
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Figure 1-4 
 
Fig.1-4. Schematic structures of OS-9 isoforms
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Chapter 2: Two Mutations Impair the Stability and Function of Ubiquitin-
Activating Enzyme (E1) 
 
Abstract 
Protein ubiquitination plays critical roles in the regulation of multiple cellular processes 
including cell cycle progression, signal transduction, oncogenesis and hypoxic response. 
TS20 is a Balb3T3-derived cell line in which protein ubiquitination is inhibited at 
restrictive temperature (39°C). While TS20 has been used to elucidate the degradation of 
many important proteins such as p53, p27, HIF-1, and ornithine decarboxylase, the 
molecular basis of its temperature sensitivity has not been fully determined. We cloned 
full-length E1 cDNA from TS20. Sequencing analysis revealed two point mutations 
(nt736G to A and nt2313G to C) that lead to substitution of aa189A to T and aa714W to 
C, respectively. Transient transfection assays revealed that the mutant E1 was less stable 
than the wild-type, and restrictive temperature (39°C) accelerated its degradation. Under 
permissive temperature, reverting aa714C to W significantly improved E1 stability. 
Under restrictive temperature, correction of both mutations was required to fully restore 
E1 stability. Similar results were observed when the mutants were expressed in non-TS20 
cells, indicating the mutations are sufficient for the thermo sensitive phenotype of E1 
observed in TS20 cells. Functionally, reverting aa714C to W was sufficient to repress the 
accumulation of HIF-1and to support TS20 growth at 39°C. Our data conclusively 
demonstrate that mutations intragenic to UVBE1 cause E1 instability, which leads to 
deficiency of E1 function. Our data establish the molecular basis for unambiguous 
17 
 
 
 
 
interpretation of experimental data based on TS20 cells, and provide new insight into the 
structural determinants of E1 stability. 
 
Introduction 
Covalent attachment of one or more ubiquitin (Ub) monomers to proteins expands 
proteomic diversity and provides a way to control protein levels and function. It has been 
well established that ubiquitination plays critical roles in modulating a variety of cellular 
processes, including cell cycle progression, immune responses, differentiation, signal 
transduction, protein trafficking and quality control (Schulman and Harper 2009). The 
most prominent function of  ubiquitination is manifested by ubiquitination-proteasome 
pathway for protein degradation within cells, where a target protein is sequentially 
labeled with Ub molecules, yielding a polyubiquitin chain for rapid proteolysis via the 
26S proteasome (Schwartz and Ciechanover 1999). The proteolytic role of 
polyubiquitination depends on the specific linkages between Ub monomers through 
amino acid residue 48-Lys. HIF-1 and P53 are among the best known targets of the 
U.P.S. Defects in this pathway have been associated with various diseases, such as 
cancers, diabetes and neurodegenerative disorders (Ciechanover 2005; Goldberg 2007).  
 
In addition to regulating protein stability, ubiquitination also participates in a variety of 
non-proteolytic functions with the attachment of a single Ub molecule, also known as 
monoubiquitination, or the assembly of polyubiquitin chain through alternative lysyl 
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residues within Ub. Monoubiquitination has been implicated in endocytic signaling, 
introcellular vesicle dynamics, signal transduction, protein translocation, DNA 
replication, and transcription regulation (Terrell, Shih et al. 1998; Hicke 2001; 
Mukhopadhyay and Riezman 2007).  Monoubiquitination of H2A, for example, has been 
associated with DNA replication and cell proliferation (Wang, Wang et al. 2004). 
Polyubiquitination through Lys63 linkage has been implicated in signaling activation, 
receptor endocytosis, intracellular protein trafficking and DNA damage repair (Galan and 
Haguenauer-Tsapis 1997; Pickart and Fushman 2004; Elsasser and Finley 2005; 
Friedberg, Lehmann et al. 2005). 
 
Ubiquitination processes are mediated sequentially through Ub-activating (E1), Ub-
conjugating (E2), and Ub-protein ligase (E3) multienzyme cascades (Hershko, Heller et 
al. 1983; Hershko and Ciechanover 1998). In mammalian cells, there are dozens of E2s, 
and several hundred E3s. However, there is a single E1 enzyme for the entire array of 
downstream reactions. Ub is first activated by E1, forming a high energy thioester bond 
with the E1. The E1-Ub thioester complex is then recognized by an E2, and the thioester-
linked Ub is transferred to E2. Finally, E2-Ub thioester complex uses the energy stored in 
the E2-Ub thioester bond to ubiquitinate target proteins, either directly or through 
substrate specific E3s complex (Haas and Rose 1982). Therefore, by catalyzing the initial 
step of ubiquitination, E1 plays an essential role in all ubiquitination processes. 
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TS20 is a Balb3T3-derived temperature sensitive cell line which arrests at S phase of the 
cell cycle with dramatically reduced protein ubiquitination at restrictive temperature 
(39°C) (Zeng, Donegan et al. 1984; Chowdary, Dermody et al. 1994). Previous studies 
showed that shifting TS20 cells from 35°C to 39°C caused rapid degradation of E1 
proteins (Chowdary, Dermody et al. 1994; Salvat, Acquaviva et al. 2000). Since 
exogenous expression of human E1 restored normal ubiquitination and rescued TS20 cell 
growth at 39°C, TS20 has been assumed to carry a temperature sensitive E1 (Chowdary, 
Dermody et al. 1994). Since its establishment, this cell line has contributed to the 
elucidating of the degradation pathways for many important proteins. Based on studies 
with TS20 cells, the turnover of p53 and HIF-1, for example, were demonstrated to 
depend on the ubiquitination-proteasome pathway (Chowdary, Dermody et al. 1994; 
Salceda and Caro 1997). In recent years, ubiquitination-independent proteasomal 
degradation pathway and its important roles have been discovered (Rosenberg-Hasson, 
Bercovich et al. 1989; Shirane, Harumiya et al. 1999; Asher, Lotem et al. 2002; Kong, 
Lin et al. 2006; Liang, Kong et al. 2006). Since complete lack of E1 activity leads to cell 
death, the temperature sensitive TS20 cell line provides a particularly important tool to 
study the ubiquitination-independent degradation pathway. However, the molecular 
nature of the mutation in TS20 cell has not been determined. The complexity of 
biological system and lack of direct evidence of E1 mutation complicate the 
interpretation of experimental observations based on this cell line. Among several 
alternative explanations, one example is that the temperature sensitive phenotype could 
be caused by a mutation extragenic to E1 gene (UBA1 or UBE1), but regulates stability of 
proteins including E1.  
20 
 
 
 
 
 
We report here the identification of two point mutations on E1 cDNA isolated from this 
cell line, and provide conclusive evidence to support that those two mutations are 
sufficient to cause the temperature sensitive phenotype. We further show that reverting of 
these mutations to wild type is sufficient to correct the temperature sensitive phenotype. 
We also show that the stabilization of E1 and the disposal of mutant E1 proteins require 
active processes of living cells. Our study provides the molecular basis for unambiguous 
interpretation of experimental data based on TS20 cells. 
 
Materials and Methods 
Cell culture and transfection 
Balb/c 3T3 mouse embryo fibroblast derived TS20 cells were kindly provided by Dr. 
Ozer (UMDNJ, New Jersey). Both TS20 and HEK 293T lines were maintained in 
DMEM medium supplemented with 10% fetal bovine serum, L-glutamine (Invitrogen), 
and mix of other amino acids (Mediatech). TS20 cells were maintained at 35°C 
(permissive temperature). 
 
Plasmid DNA was isolated by using a Maxiprep kit (Qiagen). TS20 or HEK 293T cells 
were transfected using Lipofectamine 2000 (Invitrogen) by following the manufacturer's 
instructions. Cells were pre-plated in 100-mm plate the day before transfection. When 
they reach about 90% confluence the next day, 6 g (for TS20 cells) or 10 g (for 293T 
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cells) of plasmid DNA mixed with 18 µl or 30 l Lipofectamine 2000 respectively, were 
added to the cells. Cells were trypsinized 24 h after transfection, divided equally, and 
cultured in 100-mm plates for non-permissive temperature treatment and Western blot 
analysis. 
 
Cloning, sequencing and site-directed mutagenesis 
Total RNA was isolated from TS20 cells by using RNAeasy Mini kit (Qiagen). E1 full 
length cDNA was synthesized by reverse transcription and further PCR-amplified by E1 
specific primers (5’-GGAATTCCAATGTCCAGCTCGCCGCTGTCC-3’ and 5’- 
CCGCTCGAGTCAGCGAATGGTATATCGGAC-3’, EcoRI and XhoI sites are 
underlined respectively). The PCR product which was first cloned into pGEM T-Easy 
vector (Promega), sequenced and compared with wild-type sequenced in database 
(GeneBank). The TS20 E1 cDNA containing two mutations in the pGEM T-Easy vector 
was digested with EcoRI and XhoI and inserted into pCDNA3-FLAG to generate pflag-
E1
189T, 714C
 in which E1
189T, 714C
 is expressed as a fusion with Flag.   
 
To revert aa189T to A in E1, site-directed mutagenesis PCR was performed by using 
primers (Forward: 5'-GTATCAAGCTAGTGGTGGCAGATACAAGAGGCCTG-3'; 
Reverse: 5'-CAGGCCTCTTGTATCTGCCACCACTAGCTTGATAC-3'). Similarly, 
primers (Forward: 5'-CCTGCCACCACTGGCACACCCAGTACT-3'; Reverse: 5'-
AGTACTGGGTGTGCCAGTGGTGGCAGG-3') were used to revert aa714C to T. Prior 
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to transformation, the resulting PCR product was digested with DpnI to remove template 
pflag-E1
189T, 714C 
plasmid DNA. The mutant plasmids expressing flag-E1
714C
, flag-E1
189T 
or flag-E1
wt
 which was derived from a double mutation of E1
189T, 714C
, were confirmed by 
DNA sequencing. 
 
Antibodies, cell Lysate preparation, and western blotting 
Mouse anti-Flag and anti--tubulin antibodies were purchased from Sigma-Aldrich (St. 
Louis, MO). Rabbit anti-E1, anti-HIF-1 -C-terminal Ubiquitin and anti-Ubiquitin 
antibodies were from Cell Signaling (Beverly, MA), Novus Biologicals (Littleton, CO), 
Epitomics (Burlingame, CA) and Enzo Life Sciences (Plymouth Meeting, PA), 
respectively. Horseradish peroxidase-coupled secondary antibodies were from Sigma-
Aldrich (St. Louis, MO) and Invitrogen (Carlsbad, CA).  
 
For Western blot analyses, cells were lysed in urea buffer (8 M urea, 10 mM Tris, 10% 
glycerol, 1% SDS, 5 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1× 
protease inhibitor mix, pH 6.8) on ice with an Ultra-Turrax T8 homogenizer (IKA GmbH 
& Co.) for 60 s. Proteins in the lysates were separated on a 4–20% gradient SDS-PAGE 
(Bio-Rad), and then electrotransferred onto a polyvinylidene difluoride membrane. The 
membrane was processed in subsequent steps with blocking with 5% milk in TBST, 
incubation with specific primary antibody, washing in TBST and incubation with 
23 
 
 
 
 
horseradish peroxidase-labeled secondary antibody. The membranes were finally 
developed with the ECL Plus system (Amersham Biosciences). 
 
Immunoprecipitation assays 
TS20 cells (3×106 cells per 10 cm plate, 2 plates) were transfected with a total of 14 g 
of each pflag-E1 constructs. After 24 h, cells were consolidated and redistributed into 4 
plates. After 20 hr, 2 plates were cultured at 35 and 2 plate were cutlured at 39 for 6 h. 
Cells were lysed with IP buffer (50 mM Tris-HCl, 300 mM NaCl, 1% triton-×-100, 5 
mM EDTA, 50 mM NaF, Na3VO4 and Protease Inhibitor Cocktail, (Roche Applied 
Science, Indianapolis, IN)). Flag-E1 proteins were immunoprecipitated by using anti-flag 
antibody and protein G agarose gel (Thermo Fisher Scientific, Rockford, IL), followed by 
immunoblot assay with an antibody against E1. 
 
In vitro transcription- translation and protein stability analysis 
In vitro E1 protein translation was achieved by using TNT T7-Coupled Wheat Germ 
Extract System (Promega) by following the manufacturer's instructions. 1 µg of each E1 
constructs were added to the reaction mixture to generate mRNA, and the translation was 
carried out in the mixture with [
35
S] methionine at 30°C for 1 h. The translation product 
is incubated with TS20 cell lysate for 1, 2, and 4 hours, respectively. The turnover of E1 
proteins was compared by quantification of [
35
S] methionine-labeled polypeptides 
following SDS-polyacrylamide gel electrophoresis separation. 
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Establishment of stable cell lines  
TS20 cells were transfected with pflag-E1
189T 
or pflag-E1
wt 
constructs using the method 
described above.  After culturing at 39°C for 3 weeks, surviving clones from each 
transfection were selected and expanded as stable cell lines, named E1
189T
 and E1
wt
 cells, 
respectively.  
 
Cell proliferation analysis 
Cells were plated in triplicate in 96-well plates at a density of 1×10
4
 cells/well.  Cell 
numbers were examined after 1, 3, 6 and 7 days using the CyQUANT® NF-Cell 
Proliferation Kit (Invitrogen) with reference to standard curves obtained from each of the 
tested cell line. 
 
Fluorescent staining and microscope  
TS20, E1
189T
 and E1
wt
 cells were plated in 8-well chamber slides (BD Biosciences). Cells 
were incubated at 35°C or 39°C for 18 and 24 hours, respectively. Viability and induction 
of cell death were examined by using apoptosis/necrosis detection kit (Enzo) where cells 
was stained with annexin V-Cyanine-3/7-AAD according to the manufacturer’s 
recommendations. Cells were visualized by confocal microscopy (Fluoview 1000; 
Olympus). 
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Results 
Identification of two missense mutations in E1 isolated from TS20 cells 
It has been shown that human E1 gene rescues TS20 cells at 39°C (Chowdary, Dermody 
et al. 1994), suggesting that the temperature-sensitive phenotype might be caused by the 
defect of the endogenous E1 function. However, it did not rule out the possibility that the 
temperature sensitive phenotype was caused by an event extragenic to E1 gene, which 
affected the protein stability of murine E1.  To precisely define the genetic defect that 
impairs E1 function in TS20 cells, we cloned E1 cDNA from TS20 cells by RT-PCR. 
Sequencing analysis showed two missense mutations at nt736 and nt2313 on E1 
transcripts (NCBI Reference Sequence: NM_001136085.1), causing two amino acid 
substitution (from aa189A to T and aa714W to C, respectively) (Fig. 2-1A and B). These 
two mutations have been confirmed by repeated RT-PCR and sequencing analysis of 
independently isolated cDNA clones. In addition, sequencing analysis of genomic DNA 
isolated from TS20 cells confirmed the mutations in one allele of E1 gene. Thus, these 
two mutations unlikely represent artifacts caused by the cloning procedures. We note that 
all cDNA clones sequenced showed the same mutations, consistent with the established 
notion that the other allele of E1 gene is not transcribed due to X-chromosomal 
inactivation.  
Structurally E1 protein consists of four functional domains (Fig. 2-1C): adenylation 
domains, which is composed of two sub-domains named inactive and active andenylation 
domains (IAD and AAD, respectively); two catalytic cysteine half-domains which are 
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named first and second catalytic cysteine half-domains (FCCH and SCCH, respectively); 
a four-helix bundle (4HB) domain; and C-terminal ubiquitin-fold domain (UFD)(Lake, 
Wuebbens et al. 2001; Walden, Podgorski et al. 2003; Lois and Lima 2005; 
Szczepanowski, Filipek et al. 2005; Lee and Schindelin 2008). Specifically, the A to T 
mutation lies within the IAD, and the T to C mutation lies within the second catalytic 
cysteine half-domain (Fig. 2-1C). Both amino acid residues are highly conserved among 
species range from invertebrates to vertebrates (Fig. 2-1D), underlying their potential 
importance.  
 
The W to C substitution affects E1 stability and function at restrictive temperature 
To determine whether these two mutations directly cause the temperature sensitive 
phenotype of TS20 cells, we performed site-directed mutagenesis assay to revert these 
two mutations one by one back to wild type. The revertant E1 constructs are named as 
pflag-E1
714C
, pflag-E1
189T 
and pflag-E1
WT
. 
We then examined the expression levels of flag-E1 proteins in TS20 cells at permissive 
(35°C) or restrictive temperature (39°C for 6 h) in cultured cells. At 35°C, all four flag-
tagged E1 proteins (pflag-E1
189T, 714C
, pflag-E1
714C
, pflag-E1
189T 
and pflag-E1
WT
) were 
readily detected (Fig. 2-2A). However, shifting cells to 39°C remarkably reduced the 
protein levels of E1
189T, 714C
 and E1
714C
. Protein level of E1
189T
 was also slightly reduced 
while E1
WT
 level was generally the same at 39°C (Fig. 2-2A). These data showed that W 
to C substitution is the major cause of reduced E1 levels in TS20 cells, whereas A to T 
substitution plays a secondary role in the temperature sensitive phenotype.  
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We tested the in vitro translation capability of those constructs in vitro by using wheat 
germ extract transcription/translation system. In this system, all constructs were 
transcribed and translated at similar efficiency (Fig. 2-2B).  
 
Mutation triggers proteasome–dependent degradation of E1 proteins 
To explore if the identified E1 mutations were sufficient to cause E1 instability and to 
exclude any involvement of other genetic alteration extragenic to E1, we tested the 
stability of those constructs in HEK293T cells. Similarly, the expression levels of E1 
mutants with W to C substitution were remarkably reduced when cultured at 39°C (Fig. 
2-3A).  
In living cells, proteins are commonly degraded by either ubiquitin-proteosomal system 
or the lysosomal system. To examine which cellular mechanism is involved in the 
temperature triggered degradation of E1 mutant proteins, we treated cells with 
proteasome inhibitor MG132 or lysosome inhibitor ammonia chloride at 39°C. Data 
shown in Fig. 2-3B indicated that the blockage of proteasome activity restored the level 
of E1 mutants.  However, inhibition of lysosome function failed (Fig. 2-3C). These data 
demonstrated that W to C substitution triggers proteasome-dependent degradation of the 
mutated E1.  
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Revertants rescue TS20 proliferation at restrictive temperature  
Restrictive temperature inactivates E1 and causes cell death and growth arrest. We next 
examined whether expression of E1 revertants was able to rescue TS20 cells at 39°C. We 
transiently transfected TS20 cells with the E1 construct to overexpress the corresponding 
E1 proteins. Two days after transfection, cells were shifted from permissive temperature 
to 39°C and incubated for another 3 days. We observed that cells transfected with wild 
type E1 or C to W revertant E1 survived and continued proliferation. However, TS20 
cells over expressing either E1
714C 
or E1
189T, 714C
 retained their temperature sensitive 
phenotype and no cells survived at 39°C after three days (Fig. 2-4A). Together, we 
conclude that the W to C mutation is the major determinant of the temperature sensitive 
phenotype. 
 
Stable transfected revertants restore normal E1 function and cell proliferation 
To examine whether C-W revertants can restore the normal function of ubiquitin 
proteasome pathway, we established two cell lines expressing mutant E1 by transfecting 
TS20 cells first at 35°C followed by selecting surviving colonies at restrictive 
temperature. After incubation at 39°C for 4 weeks, colonies were formed from cells 
transfected with either E1
189T
 or wild type E1. Transfection of either E1
714C 
or E1
189T, 714C
 
failed to establish any clones, again suggesting 714C mutation is the major contributor of 
the temperature sensitive phenotype. Next, established individual colonies for E1
189T
 and 
wild type E1 were expanded and analyzed for E1 stability and activity. We observed that 
the E1
189T
 protein levels in stable cell lines were slightly affected after incubation at 39°C 
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for 3 h (Fig. 2-5A), suggesting that the 189T mutation also partly causes E1 instability. 
Nevertheless, this mutation was not the major cause of cell death or growth arrest, as 
demonstrated by its successful growth at 39°C. 
One of the biological consequences of TS20 cells at restrictive temperature was the 
accumulation of short life proteins, such as HIF-1 and p53, whose levels are mainly 
regulated through ubiquitination-proteasome pathway (Chowdary, Dermody et al. 1994; 
Salceda and Caro 1997). To test whether the stable cell lines have sufficient E1 activity to 
support the polyubiquitination and the degradation of short life proteins at 39°C, we 
examined HIF-1 levels in those cell lines under different culture conditions. Consistent 
with previous reports (Salceda and Caro 1997), TS20 cells accumulated HIF-1 when 
cultured at 39°C, and cells stably expressing E1
wt
 cells didn’t accumulate HIF-1 at 
either 35°C or 39°C (Fig. 2-5B), suggesting expression of wild type E1 recovered 
sufficient E1 activity to fully restore polyubiquitination under the normoxic condition and 
degrade HIF-1, a normal cellular function essential for oxygen sensing and homeostasis 
(Semenza and Wang 1992; Semenza, Roth et al. 1994). At 39°C, the level of HIF-1a 
slightly increased in E1
189T
 cells, suggesting that expressing E1
189T
 restore the normal 
function of the polyubiquitination of HIF-1  
Ubiquitination profiling analysis using anti-ubiquitin antibody revealed that cells 
expressing either E1
wt
 or E1
189T
 showed significantly increased levels of H2A 
monoubiquitination (Wang, Wang et al. 2004). Since H2A monoubiquitination plays a 
critical role in chromosome replication and cell cycle progression, this observation 
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supports the notion that proteins involved in cell cycle may be preferred target of E1 
activity and ubiquitination (Fig. 2-5C). 
E1-dependent ubiquitin proteasome system controls some major events in cell cycle 
progression, and it has been reported that TS20 cells were arrested at S1 phase shortly 
after shifting to 39°C (Zeng, Zannis-Hadjopoulos et al. 1985). Considering that multiple 
cellular processes depend on protein ubiquitination, we next asked how cell proliferating 
rate is related to E1 activity. To examine if E1 activity provided by E1
189T
 is sufficient to 
support cell proliferation, we compared the growth curves of these cell lines with TS20 
cells. We observed that cells expressing E1
189T
 grew faster than either E1
wt
 or the parental 
TS20 cell lines (Fig. 5D), suggesting that fully restored E1 activity may be not absolutely 
required to support cell proliferation.  
 
Defects in E1 cause TS20 cells apoptotic death at restrictive temperature  
To determine which death pathway is involved in TS20 cells at restrictive temperature we 
assessed morphologic evidence of apoptosis and necrosis in the presence or absence of 
the binding of annexin V with phosphatidylserine on the extracellular face of the plasma 
membrane, a hallmark of early apoptosis, or DNA intercalating dye 7-AAD labeled 
nucleus which represents late stage apoptosis and necrosis. Apoptosis/necrosis detection 
assay confirmed that restrictive temperature caused apoptosis of TS20 cells. Although 
stable transfected E1
189T
 cells could survive at restrictive temperature, increased apoptotic 
cells were observed, however, in E1
wt
 cells, no apoptotic cells were observed at 39°C 
(Fig.2-6A and B).  
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Defects in E1 accelerate mutant cells death under inhibition of proteasome.  
Since it has been shown in transient transfection in HEK 293T cells that the degradation 
of E1 mutants is proteasome-dependent, and inhibition of the proteasome retained E1 
levels at restrictive temperature, as well as accumulation of ploy-ubiquitinated proteins. 
We asked whether inhibition of proteasome affects viability of mutant cells at restrictive 
temperature. To test this, E1
189T, 714C
, E1
714C 
and E1
wt
 cells were treated with proteasomal 
inhibitor, MG132 for 24 hours at 35°C or 39°C. Cell morphology was imaged before and 
after treatment. Interestingly, inhibition of protein degradation had a devastate effect on 
the viability of all three cell lines. There were almost no cells adherent to the plate from 
both E1 mutant cells after treatment with proteasomal inhibitor, however, there was a 
significant number of cells still adherent to the plate with wild type E1(Fig.2-7).    
 
Discussion 
In this study, we identified two point mutations causing aa189A to T and aa714W to C 
substitutions in E1 isolated from the temperature sensitive TS20 cells. Characterization of 
these mutations reveals that aa714T to C substitution is the major cause of E1 instability. 
In addition, aa189A to T mutation also affects E1 stability at restrictive temperature. 
Inhibition of proteasome activity increased the protein levels of E1 mutants while 
inhibition of lysosomal protease activity had no effect. Our data demonstrate that E1 
mutations are the bona fide cause of the temperature sensitive phenotype of TS20 cells, 
32 
 
 
 
 
which is mediated by proteasome-dependent degradation of mutant E1, and does not 
require any other genetic alteration extragenic to UBA1 gene. 
 
Previously, we reported that certain chemotherapeutic drugs triggered ubiquitination-
independent, but proteasome-dependent degradation of HIF-1, partly based on data 
obtained from TS20 cells (Kong, Lin et al. 2006). Because of lack of direct evidence of 
E1 mutation, one major concern raised by other researchers was that the complexity of 
the biological system may provide alternative explanations for E1 inactivation at 
restrictive temperature. Specifically, it is equally possible a mutation extragenic to the E1 
gene may be responsible for the degradation of mutant E1 and HIF-1. The same concern 
can be raised for ubiquitination-independent degradation of other proteins demonstrated 
with TS20 or other cell lines with similar temperature sensitive E1. Our data presented 
here unambiguously validated that E1 mutations are the bona fide cause of the 
temperature sensitive phenotype of this cell line, thus validating the ubiquitination-
independent protein degradation observed with this cell line. 
 
The precise mechanism underlying the temperature-triggered degradation of mutant E1 
remains unclear. One possibility is that mutations in E1 increase E1 misfolding, which 
gives rise to structurally unstable E1 proteins. When cultured at permissive temperature, 
subtle folding defects may be recognized by protein chaperone complexes, such as heat 
shock protein 70 and 90 complexes, which facilitate mutant protein stability by refolding 
or interacting with the mutant proteins. Restrictive temperature leads to extensive 
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misfolding of E1 and other cellular proteins, which may eventually overwhelm the 
folding capacity of the cellular chaperone system. Finally, the misfolded E1 is eventually 
degraded by the proteasome. Interestingly, the 714W to C mutation turns out to be the 
major contributor to the mutant E1 instability. It is possible that the aberrant cysteine 
residue interrupts the folding processes of other sulfhydryl groups on E1 protein. 
 
An intriguing question is whether the temperature-triggered degradation of mutant E1 
itself depends on ubiquitination. While our data support that under restrictive temperature, 
proteasome activity is required to degrade mutant E1, it is assumed that under such 
condition, the ubiquitination process as a whole is generally inhibited. One possible 
explanation is that mutant E1 proteins are preferred substrates for ubiquitination, so even 
very low residual levels of E1 activity would be sufficient to cause its ubiquitination. Our 
data showed that in the presence of MG132, the accumulated mutant E1 proteins did not 
have an apparent increase in molecular weight, a change that is normally associated with 
protein ubiquitination. In addition, those E1 mutant proteins also failed to be recognized 
by anti-ubiquitin antibody in Western blotting. Taken together, those observations may 
suggest that under restricted temperature, the degradation of mutant E1 proteins are 
unlikely dependent of ubiquitination. An alternative possibility is that proteasome-
mediated degradation of mutant E1 involves the ubiquitination-independent pathway, 
which has been reported for the degradation of p53, p27, ODC and HIF-1 under certain 
conditions (Rosenberg-Hasson, Bercovich et al. 1989; Shirane, Harumiya et al. 1999; 
Asher, Lotem et al. 2002; Kong, Lin et al. 2006). However, even under permissive 
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temperature, mutant E1 proteins carrying aa714C are less stable, and their levels could 
not be enhanced by exposing cells to proteasome inhibitor MG132 (data not shown), 
suggesting the existence of other non-proteosomal mechanisms that affect mutant E1 
expression under this condition. 
 
E1 functions at the initial step of multiple ubiquitination pathways. Functionally, it 
interacts with dozens of E2s and hundreds of E3s.  Mutation in E1 may affect its 
preference of interacting with different E2s or E3s. Monoubiquitinated H2A (uH2A) has 
been linked to chromosome replication and cell proliferation (Vassilev, Rasmussen et al. 
1995). The H2A E3 ligases Ring1B and RNF8 have been demonstrated to play essential 
roles in cell proliferation (Tuttle, Bothos et al. 2007; Plans, Guerra-Rebollo et al. 2008). 
A comparison of the stable cell lines expressing E1189T or E1wt with TS20 at 
permissive temperature revealed that both E1189T and E1wt were stable, and the over all
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ubiquitination levels were similar. However, the monoubiquitination level of H2A in 
TS20 was much lower than that of E1189T and E1wt cells. Interestingly, the enhanced 
H2A monoubiquitination levels seem to be associated with the cell proliferation rate (Fig. 
2-5).  
 
These data suggest that unlike aa714W to C mutation in the catalytic cysteine domains, 
aa189A to T mutation may have a subtle defect limited to selected non-preferred 
substrates, but it does not affect cell proliferation processes.  
 
In summary, our study provided molecular and genetic evidence that E1 mutation is the 
determining factor responsible for the associated phenotype of TS20 cells. The 
temperature sensitive proteasome-dependent disposal of mutant E1 at restrictive 
temperature suggests an active quality control system for E1 protein. The TS20 cell line 
and stable cell lines expressing E1 mutants will become valuable tools in exploration of 
mechanisms underlying both ubiqutination-dependent and ubiquitination-independent 
protein degradation pathways. These cell lines will facilitate the study of other cellular 
processes regulated by protein ubiqitination.  
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Figure 2-1 
 
 
 
Fig.2-1. Identification of two missense mutations in E1 from TS20 cells. A and B: 
Several independently isolated E1 cDNA clones derived from TS20 cells were sequenced. 
Two point mutations, nt736A to G and nt2313 C to G were identified, which change 
aa189 T to A and aa714 C to W, respectively. Representative sequencing data were 
shown. C: The schematic structure of E1 protein showed. E1 protein consists of four 
functional domains: adenylation domains is composed of two sub-domains inactive and 
active andenylation domain, IAD and AAD, respectively; catalytic cysteine domains is 
composed of two half-domains named first and second catalytic cysteine half-domain, 
FCCH and SCCH, respectively; a four-helix bundle(4HB); and C-terminal ubiquitin-fold 
domain(UFD). D: Protein sequences of mouse E1 were aligned with that of other species. 
Results reveal that both aa189A and aa 714W residues are highly conserved among 
evolutionarily distant species. Alignments were generated using BioEdit.. 
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Figure 2-2 
 
 
 
Fig.2-2. 714W to C substitution affects E1 stability in TS20 cells. A: Four E1 
constructs: pflag-E1189T, 714C pflag-E1714C, pflag-E1189T, and pflag-E1WT together 
with empty control vector were transfected in TS20 cells, and each transfection was split 
into two equal plates 24 h after transfection. At 44 h post transfection, one plate was 
shifted to 39°C for 8 h. Cell lysates were collected. Since the transient expression levels 
of mutant E1 in TS20 cells was extremely low, E1 proteins were enriched by 
immunoprecipitation using anti-flag antibody and detected using anti-UBE1 antibody. 
-tubulin was 
detected by anti- -tubulin antibody. B: All four E1 constructs were in vitro transcribed 
and translated by using TNT T7-coupled Wheat germ extract system. Proteins levels of 
E1, indicated by incorporated [
35
S] methionine, were detected by autoradiography after 
resolving on SDS-polyacrylamide gel electrophoresis (SDS-PAGE). 
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Figure 2-3 
 
 
 
Fig.2-3. E1 mutations are sufficient to trigger proteasome–dependent 
degradation. A: Four E1 constructs: pflag-E1
189T, 714C
 pflag-E1
714C
, pflag-E1
189T
, and 
pflag-E1
WT
 were transfected into 293 cells. Plasmid pflag-HDAC1 was co-transfected as 
a control for transfection efficiency. Each transfected dish was split into two equal plates 
24 h after transfection. At 44 h post transfection, one dish was shifted to 39°C for 8 h. 
Transiently expressed flag-E1 and flag-HDAC1 proteins were detected by using anti-Flag 
antibody. B: Transiently transfected cells were cultured at 39°C for 8 h with either 
DMSO (control) or proteasome inhibitor MG132. Protein levels of Flag-E1 were 
examined by western blotting. C: Transiently transfected cells were cultured at 39°C for 
8 h with either NaCl (control) or lysosome inhibitor NH4Cl. Protein levels of Flag-E1 
were examined by Western blotting.  
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Figure 2-4 
 
 
 
 
Fig.2-4. Reverting 714C to W rescue TS20 surval and proliferation at restrictive 
temperature. TS20 cells were transiently transfected with each of the E1 constructs to 
overexpress the corresponding E1 proteins. Two days after transfection, cells were 
shifted from permissive temperature to 39°C, and incubate for another 3 days. Cell 
morphology was photographed immediately before or 72 hours after shifting to 39°C.  
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Figure 2-5 
 
 
Fig.2-5. Stable expression of 714C to W revertant restores E1 function. A: Two 
newly established cell lines E1
189T
 and E1
wt
 together with their TS20 cell line, which 
contains E1
189T,714C
 mutation, were analyzed. Cells were culture at permissive 35°C or 
restrictive 39°C for 1 or 3 h. Cycloheximide (Sigma) were used to block de novo 
translation and test the protein stability. Total E1 protein levels were detected by using an 
anti-UBE1 antibody. -tubulin was detected as a loading control by using an anti- -
tubulin antibody. B: The three cell lines used in A were cultured at both temperature and 
restrictive temperature points. Flag-E1 and total E1 protein levels were detected using 
anti-flag and anti-UBE1 antibodies, respectively. Ubiquitin proteasome pathway targeted 
protein, HIF-1A level was determined as indicators of the ubiquitin-proteasomal 
-tubulin levels were examined as a loading control. C: The three cell 
lines were assayed for a cell proliferation rates at permissive temperature. Cell numbers 
(reflected by DNA contents) were determined at days 0, 1, 3, 6 and 7. D: Ubiquitination 
profile in the three cell lines were examined by using anti-ubiquitin antibody, and a band 
represents monoubiquitinated H2A (uH2A) which was confirmed by anti-Ub-H2A 
antibody was marked.   
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Fig.2-6. Defect in E1 causes TS20 cells apoptotic death at restrictive. Three stable cell 
lines were tested for apoptosis/necroses under restrictive temperature.  Apoptosis 
detection reagent Annexin V-Cyanine-3 (blue) (A) and 7-AAD (red) (B) were shown 
cells undergoing early apoptosis or late stage apoptosis, respectively.  
Fig.2-6 
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Fig.2-7 
 
 
 
Fig.2-7. Defect in E1 accelerates mutant cells death under inhibition of proteasome. 
Three stable cell lines were cultured at restrictive temperature for 24 hours with 
inhibiting the function of proteasome using MG132. Cells were imaged using a light 
microscope before or after inhibition. 
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Chapter 3:  OS-9 regulates hypoxia-inducible factor 1 in the endoplasmic 
reticulum 
 
Abstract 
Hypoxia-inducible factor 1 (HIF-1) is the master regulator of oxygen homeostasis and 
plays critical roles in cells’ responses to multiple signaling. HIF-1 level is mainly 
regulated by an oxygen-dependent hydroxylation-ubiquitination-proteasomal system. OS-
9, a component of endoplasmic reticulum (ER)-associated protein control system, 
removes misfolded glycoproteins in the ER-associated degradation (ERAD) pathway. 
Here we demonstrate that HIF-1 is under the surveillance of the ER associated protein 
quality control system where OS-9 directly interacts with HIF-1 in ER-derived vesicles 
and promotes its degradation by the proteasome. These findings indicate a novel 
mechanism that regulates HIF-1 stability and suggests that the ER protein quality 
control system appears to participate in the surveillance of nuclear proteins.

Introduction 
Hypoxia inducible factors (HIFs) are transcriptional factors regulating hypoxic adaptation 
of cells and they play a central role in oxygen homeostasis during embryonic 
development and postnatal life (Wang, Jiang et al. 1995; Wang and Semenza 1995; 
Semenza 2002). HIFs activate a large group of hypoxia-inducible genes, including 
glycolysis enzymes and vascular endothelial growth factor (VEGF) which promote cell 
survival in low-oxygen conditions, and therefore are also involved in pathologic 
processes such as erythrocytosis, inflammation, and tumor development, angiogenesis, 
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and metastases (Ema, Taya et al. 1997; Maxwell, Pugh et al. 2001; Semenza 2001; Harris 
2002; Semenza 2002).  
 
HIFs are heterodimers formed by a highly oxygen sensitive HIF- and a constitutively 
expressed HIF- subunits (Wang, Jiang et al. 1995; Wang and Semenza 1995). With 
sufficient oxygen supply, although HIF-1 mRNA is continuously translating, newly 
synthesized HIF-1 protein is rapidly degraded by ubiquitination-proteasomal system 
(Huang, Arany et al. 1996; Salceda and Caro 1997; Kallio, Wilson et al. 1999). This 
degradation is mediated through sequential post-translational modifications of HIF-1 
that start with hydroxylation of two prolyl residues (P402 and P564) in the oxygen-
dependent degradation domain (ODD) of HIF-1 by a family of proline hydroxylases 
(PHD1, PHD2, and PHD3) (Pugh, O'Rourke et al. 1997; Huang, Gu et al. 1998; Srinivas, 
Zhang et al. 1999; Ivan, Kondo et al. 2001; Jaakkola, Mole et al. 2001; Masson, Willam 
et al. 2001; Yu, White et al. 2001). The hydroxylation modified HIF-1 is further 
recognized and ubiquitylated by an E3 ubiquitin ligase complex containing the von 
Hippel-Lindau tumor suppressor protein for degradation by the 26 S proteasome (Salceda 
and Caro 1997; Huang, Gu et al. 1998).  
 
In addition to hydroxylation, HIF-1 protein has also been reported to be modified by 
nitrosylation, phosphorylation, acetylation, carboylation and sumoylation, and these 
modifications can affect protein folding, localization, stability and transactivation activity 
(Bardos and Ashcroft 2005). The quality control of these modifications, therefore, is 
essential for HIF-1 function and regulation. Eukaryotic cells have evolved protein 
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quality control systems to detect, repair and degrade aberrant protein which can arise 
from mutation, environmental stress, incorrect folding, transcriptional or translational 
errors, imbalanced subunit synthesis, and improper modification and trafficking (Bukau, 
Weissman et al. 2006; Hartl and Hayer-Hartl 2009).  
 
The endoplasmic reticulum PQCS machinery has been well defined. Nascent 
polypeptides containing an N-terminal signal peptide are transported into the ER lumen 
by the Sec61 translocon complex (Klappa, Zimmermann et al. 1994; Oliver, Jungnickel et 
al. 1995; Wiertz, Tortorella et al. 1996; Kalies, Rapoport et al. 1998). Those polypeptides 
containing Asn-X-Ser/Thr motif are cotranslationally modified with N-linked glycans and 
then undergo a series lectins/chaperones mediated folding by calnexin, calreticulin, Bip, 
PDI and/or Grp94 containing chaperone complexes (Trombetta and Helenius 1998; High, 
Lecomte et al. 2000). Unfolded glycoproteins may be subjected to removal by other 
lectins such as EDEM, XTP3-B and OS-9, which facilitate the retrotransolation of these 
substrates to the cytosol for ubiquitination and degradation by the 26S proteasome 
(Christianson, Shaler et al. 2008; Hosokawa, Kamiya et al. 2009; Bernasconi, Galli et al. 
2010; Hosokawa, Kamiya et al. 2010).  
 
Here we specifically addressed whether OS-9 plays a role in the regulation of HIF-1 
within the ER protein quality control system. We show that the ER-lumen localization of 
OS-9 is essential for promoting exogenously expressed HIF-1 degradation and 
mislocation of OS-9 to the cytosol results in the accumulation of HIF-1 within vesicles 
originated from the ER. Further experiments confirmed that OS-9 physically interacts 
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with both HIF-1 and polyubiquitinated-HIF-1, especially under the stress condition. 
Although over-expression of OS-9 had no effect on HIF-1 transactivating activity, 
knocking down OS-9 rescued HIF-1 function inhibited by tunicamycin, an ER-stress 
inducer. Our findings therefore indicate that OS-9 plays a critical role in regulating the 
quality of HIF-1 within the ER and in so doing may provide a novel mechanism for 
modulating HIF-1 function. The ER protein quality control system appears to 
participate in the surveillance of the nuclear proteins.  
 
Materials and Methods 
Cell cultures and transfections 
Hep3B and HeLa cells were obtained from the ATCC and cultured according to the 
instruction. RCC4 (VHL-) cells were provided by P. Ratcliffe (Oxford University, Oxford, 
England). RCC4, and HeLa cell lines were maintained in DMEM medium supplemented 
with 10% fetal bovine serum, L-glutamine (Invitrogen), and mix of other amino acids 
(Mediatech). Hypoxia (1% O2) conditions were created in an oxygen station (In VIVO2; 
Ruskin Tech). 
 
Plasmid DNA was isolated by using a Maxiprep kit (Qiagen). Hep3b cells were 
transfected using Lipofectamine 2000 (Invitrogen), by following the manufacturer's 
instructions. Cells were preplated in 100-mm plate the day before transfection. When 
they reach about 90% confluence the next day, 6 µg  of plasmid DNA mixed with 18 µl 
Lipofectamine 2000, were added to the cells. Cells were trypsinized 24 h after 
transfection, divided equally, and cultured in 100-mm plates for non-permissive 
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temperature treatment and Western blot analysis. siRNA transfections were performed 
using the following siRNAs sequence: si1781 was targeting OS-9.1 (Forward: 
5'GAUUUGUUUCAGCUGGUG 3'; Reverse: 5'CCCACAGCUGAAACAAA 3'); si420 
was targeting both OS-9.1&2 (Forward: 5'UUCAUAGGUCCACCAGUC 3'; Reverse: 
5'GGACUCGUGGACAUAUGA 3') at a final concentration of 10nM, and cells were 
transfected twice within 48 h, and collected at the 48 h after second transfection.     
 
 
Chemicals and Reagents 
Tunicamycin (TM) and Trichostatin A (TSA) were purchased from Enzo Life Sciences 
(Plymouth Meeting, PA). Proteasome inhibitor MG132 (Z-LLL-CHO) and 
cycloheximide (CHX) were purchased from Sigma.  
 
Site-directed mutagenesis 
To delete OS-9 conserved domain, a PCR-based mutagenesis (Stratagene) approach was 
carried out by using following primers:   SP deletion, (Forward: 5'-
GACGATGACGACAAGGGCGGAATGGCGGCGGAAACG-3'; Reverse: 5'-
CGTTTCCGCCGCCATTCCGCCCTTGTCGTCATCGTC-3'); GBS deletion, (Forward: 
5'-GTTGAGCCCAATGAGAGATTCCAAGTGCGACCTT-3'; Reverse: 5'-
AAGGTCGCACTTGGAATCTCTCATTGGGCTCAAC-3'); NLS deletion, (Forward: 5'-
CACTCTCAACAAACTCATCAGGGTTGTCCCCAAAAAGC-3'; Reverse: 5'-
GCTTTTTGGGGACAACCCTGATGAGTTTGTTGAGAGTG-3'); IND deletion, 
(Forward; 5'-GCTGGAGAGGGAGGGAGGAGCTGAAGAG-3'; Reverse: 5'-
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CTCTTCAGCTCCTCCCTCCCTCTCCAGC-3'). Prior to transformation, the resulting 
PCR product was digested with DpnI to remove template pFLAG-OS-9. The deletion 
plasmids were confirmed by DNA sequencing. 
 
Antibodies, Cell Lysate Preparation, and Western Blotting 
Mouse anti--tubulin and anti-FLAG (M2) antibodies were purchased from Sigma-
Aldrich
 
(St. Louis, MO). Rabbit (MAb) anti-HIF-1, Rabbit (PAb) anti-IRE1, and anti-
HIF-1 antibodies were from, Epitomics (Burlingame, CA), Cell Signaling (Beverly, 
MA), and Novus Biologicals (Littleton, CO). Rabbit (PAb) anti-OS-9, anti-GRP94, anti-
PDI, anti-Giantin and anti-Histon3 were from Abcam (Cambridge, MA). Rabbit anti-
ERp57 was from Enzo Life Sciences (Plymouth Meeting, PA). Horseradish peroxidase-
coupled secondary antibodies were from Sigma-Aldrich (St. Louis, MO) and Invitrogen 
(Carlsbad, CA).  
 
For Western blot analyses, the method was as previously described (Lao, Chen et al. 
2011), briefly, cells were lysed in urea buffer (8 M urea, 10 mM Tris, 10% glycerol, 1% 
SDS, 5 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1× protease inhibitor 
mix, pH 6.8) on ice with an Ultra-Turrax T8 homogenizer (IKA GmbH & Co.) for 60 s. 
Proteins in the lysates were separated on a 4–15% gradient SDS-PAGE (Bio-Rad), and 
then electrotransferred onto a polyvinylidene difluoride membrane. The membrane was 
processed in subsequent steps with blocking with 5% milk in TBST, incubation with 
specific primary antibody, washing in TBST and incubation with horseradish peroxidase-
labeled secondary antibody. The membranes were finally developed with the ECL Plus 
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system (Amersham Biosciences). 
 
 
Immunoprecipitation Assays 
Hep3B cells (3 x 106 cells per 10 cm plate, 2 plates) were transfected with a total of 3.5 
ug of each pFLAG-OS-9 and pHA-HIF-1 constructs. After 24 hr, cells were 
consolidated and redistributed into 4 plates. After 20 hr, cells were lysed with IP buffer 
(50mm Tris-HCl, 300 mm NaCl, 1% triton-x-100, 5 mm EDTA, 50 mm NaF, Na3VO4 
and Protease Inhibitor Cocktail, (Roche Applied Science, Indianapolis, IN)). FLAG-E1 
proteins were immunoprecipitated by using anti-FLAG antibody and Protein G agarose 
gel (Thermo Fisher Scientific, Rockford, IL), followed by immunoblot assay with an 
antibody against FLAG tag, or OS-9.  
 
Separation of subcellular compartments  
Subcellular compartments were separated by using two methods; in the method 1 protein 
from general compartments were separated into Cytosol (C), Membrane & Organelles 
(M&O), and Nuclear (N), respectively. In the method 2, proteins from membrane (M) 
versus luminal (L) content were well separated. In method 1, according to the instruction 
(Subcellular Proteome Extraction Kit, EMD), Hep3B cells cultured in two 10-cm dish 
were detached by trypsin digestion and washed with cold PBS and centrifuged in pellet 
for stepwise extraction. Cell pellet was resuspended in 1ml buffer NO.1 and incubated at 
4°C with rotating for 10 min. After centrifugation at 2000 g for 5 min, Cytosolic 
supernatants were collected and the pellet was resuspened in 1ml buffer NO.2 and 
51 
 
 
 
 
incubated at 4°C for 30 min. After centrifugation at 5000 g for 5 min, M&O-containing 
supernatants were obtained and nuclear-containing pullet were resuspended in 1 ml buffer 
No.3 with Benzonase. After centrifugation at 8000g for 10 min, nuclear-containing 
supernatants were collected. In method 2, cells were scraped off the plate and 
resuspended in lysis buffer (10 mM triethanolamine, 10 mM acetic acid, 250 mM sucrose, 
20 mM N-ethylmaleimide, 1 mM EDTA and a mixture of protease inhibitors, pH 7.4) 
(Bernasconi, Pertel et al. 2008). Cells were broken with 10 passages through a 25-gauge 
needle and centrifuged at 2000g for 5min to get rid of nuclear debris. Supernatants wer 
ultracentrifuged at 200,000 g for 45 min. Cytosol-containing supernatants were collected 
and the endomembrane-containing pellet was washed with lysis buffer and resuspended 
in 500 ul of 100 mM NaHCO3 (PH 11.0) for 25 min to elute luminal protein. After 
ultracentrifugation at 200,000 for 45 min, the luminal fraction was collected and the 
membrane-containing pellet was dissolved in 8 M urea buffer. Proteins from different 
compartments were analyzed by western blotting. 
 
 
Fluorescent staining and microscope  
HeLa cells, transfected with pFLAG-OS-9, pFLAG-SP, pFLAG-GBS, and/or pHA-
HIF-1 constructs were plated in 8-well chamber slides (BD Biosciences) with or 
without MG132 treatment. After 24-48 h, cells were fixed with 4% paraformaldehyde for 
10 min at room temperature. Fixed cells were permeabilized with 0.2% Triton X-100 in 
PBS for 6 min. After 3 times wash with PBS, cells were incubated with PBS containing 
10% goat serum for 1h for blocking and then incubated in diluted primary antibodies in 
52 
 
 
 
 
PBS/10% goat serum for 2 h. Washed in PBS with 0.1% tween 20 for 3 times, cells were 
incubated with fluorescents linked goat anti-rabbit or mouse secondly antibodies. Cells 
were then visualized by confocal microscopy (Fluoview 1000; Olympus). 
 
qRT-PCR. 
Hep3B cells, seeded in 6 well plates, were treated as indicated. Total RNA was extracted 
using the Qiagen RNeasy kit. cDNA was synthesized by superscript II reverse 
transcriptase (Invitrogen) with random hexamers as primers. qRT-PCR was performed 
using Taqman gene expression master mix and StepOnePlus Real-Time PCR System 
(Applied Biosystems). Data were quantitatively analyzed by StepOne software with 
comparative CT method. β-actin was set as endogenous control. 
 
Results 
ER localization signal is essential for OS-9 promoted HIF-1degradation  
We had independently identified that OS-9 interacts with HIF-1 by yeast two-hybrid 
assay using a different bait amino acid (aa) 740-813 of HIF-1 (data not shown) from 
Gregg L. Semenza’s group (aa 576-826 of HIF-1). OS is ubiquitously expressed in all 
human tissues and has two major isoforms. The full-length OS-9.1 with 667 amino acids 
and OS-9.2 lacks the amino acids from 536 to 589. According to limited publications, 
OS-9 is mainly considered to be a component of ER protein quality control system, 
specifically in the degradation machinery. To further establish a potential role for OS-9 in 
regulation of the HIF-1 function, we used motif scanning to identify potential functional 
domains and made deletions in the OS-9 expression constructs. These identified domains 
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included an ER-localization signal peptide (SP), glucosidase II beta subunit-like protein 
domain (GBS), N-glycosylation site, Glu and Asp rich domain (ED-Rich), nuclear 
localization signal (NLS) and importin beta N-terminal domain profile (IND) (Figure 3-
1A). Among them, SP, GBS, NLS, and IND were used in this study.  
To confirm that OS-9 modulates HIF-1 stability in human cells, we co-transfected 
Hep3B cells with plasmids expressing GAL4-HIF-1 (740-826) and FLAG-OS-9. Over-
expression of OS-9 decreases the level of GAL4-HIF-1 (740-826) compared with co-
transfection of empty vector or antisense OS9. To determine whether decreased level of 
GAL4-HIF-1 (740-826) was caused by reduced de novo translation or accelerated 
degradation, we examined whether proteasome inhibitor MG132 was able to block OS-9 
caused decrease of HIF-1 levels. Data shown in Figure 3-1B revealed that treating cells 
with MG132 for 6 hrs effectively accumulated GAL4-HIF-1 (740-826), suggesting that 
OS-9 promotes proteasome-mediated GAL4-HIF-1 (740-826) degradation.  
We further examined whether deletion of OS-9 functional domains had any effects on 
HIF-1 stability. As shown in Figure 3-1C, both NLS and IND promoted the 
degradation of GAL4-HIF1 (740-826) in a manner similar to the wild type. Interestingly, 
SP significantly increased the level of GAL4-HIF-1 (740-826), indicating ER 
localization is essential for OS-9 promoted HIF-1degradation. Similar to the wild type 
OS-9, both NLS and IND caused reduction of HIF-1 which was blocked by 
inhibition of proteasome. In SP co-transfection, however, inhibition of proteasome had 
little effect on accumulation of GAL4-HIF-1 (740-826) compared with no-treatment, 
suggesting that SP blocked HIF-1 degradation through a pathway that is overlapped or 
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independent with the inhibition of proteasome. To rule out possible effects due to the 
GAL4 protein, we also co-transfected cells with expression vectors encoding HA-HIF-1 
and OS-9 wild type or deletions, similar effects were also observed (data not shown).  
  
OS-9 physically interacts with HIF-1  
We next sought to examine physical interaction between HIF-1 and OS-9. Human 
Hep3B cell were co-transfected with vectors expressing HA-HIF-1 with FLAG-OS-9 or 
FLAG-SP, and whole cell lysates (WCL) were immunoprecipitated with anti-FLAG or 
anti-OS-9 antibodies. Western blotting assay revealed that exogenously expressed FLAG-
OS-9 and FLAG-SP co-precipitated with exogenously expressed HA-HIF-1(Fig.3-
2A). To rule out nonspecific interaction due to overexpression of HIF-1, cells were 
transfected with vectors expressing FLAG-OS-9 or FLAG-SP and treated with 
trichostatin A (TSA), a type of histone deacetylase inhibitor that has been reported to 
induce immature HIF-1 accumulation by disruption of the HSP70/HSP90 axis, and 
together with desferrioxamine (DFX) and MG132, to block HIF-1 degradation (Fath, 
Kong et al. 2006; Kong, Lin et al. 2006; Liang, Kong et al. 2006). As shown in Fig.3-2B, 
HIF-1 was coimmunoprecipitated only in cells expressing both endogenous HIF-1 and 
FLAG-OS-9 or FLAG-SP. To investigate whether endogenous OS-9 interacts with 
endogenous HIF-1, Hep3B cells were incubated at 1% O2 condition with or without 
Mg132 and/or TSA treatment. As shown in Fig. 3-2C, more HIF-1 was 
coimmunoprecipiated in cells treated with TSA+MG132 than that in MG132 only or 
none treatment. It was noteworthy that a higher molecular weight smear band of HIF-1 
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which was usually considered as poly-ubiquitinated HIF-1 was also observed in all 
three treatments, suggesting that OS-9 may involve in an ubiquitin-proteasomal 
dependent degradation pathway of HIF-1.  
  
 
Multiple forms of HIF-1are localized in distinct subcellular compartments where 
OS-9 is present. 
Different subcellular distribution patterns of HIF-1 have been observed in different cell 
types under different conditions (Normoxia and Hypoxia), and the fact that HIF-1 can 
be shuttling between cytoplasm and nucleus in some cells even under hypoxia suggests 
that a multiplicity of factors and pathways are dynamically involved in the regulation of 
HIF-1 (Kallio, Okamoto et al. 1998; Chilov, Camenisch et al. 1999; Groulx and Lee 
2002; Zheng, Ruas et al. 2006; Moroz, Carlin et al. 2009).To investigate the intracellular 
location where HIF-1 was able to interact with OS-9, proteins separated from different 
subcellular compartments were analyzed by western blotting. We applied two strategies 
to provent hypersensitive HIF-1 degradation during the isolation processes. One was to 
stabilize HIF-1 by MG132 and DFX treatment in Hep3B cells to block protein 
degradation. Protein fractions from different subcellular compartments, such as cytosol 
(C), membrane and organelle (M&O), and nucleus (N), were isolated and confirmed with 
antibodies detecting distinct subcellular markers (Fig. 3-3A). The data shown that 
substantial amount of HIF-1 presented in the M&O fractions, as well as in the C and N 
fractions with bands shifting at different mobility, suggesting distinct post-translational 
modifications of HIF-1 in different compartments (Fig. 3-3A). OS-9 localized within 
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the M&O fraction consistent with the previously published studies. Using NaHCO3 
separation methods further confirmed that OS-9 is a luminal protein (Fig. 3-3B). The 
other strategy was using VHL-negative RCC4 (VHL-) cells which constitutively 
expressed HIF-1 at normoxic condition due to the dysfunction of hydroxylation-
ubiquitination proteasome pathway. Compared to proteins like -tubulin, CNX and 
GRP94, treating RCC4 (VHL-) cells with MG132 for just 6h resulted in robust 
accumulation of multiple forms of HIF-1 suggesting that an alternative degradation 
pathways are participating in these cells for HIF-1(Fig. 3-3C). We applied a different 
separation method to isolate proteins from cytosol (C), ER-membrane (M), ER-lumen (L) 
and nucleus (N). Data shown in Figure 3-3D revealed that consistent with our previous 
observation, multiple bands of HIF-1 with different mobility were again present in the 
distinct subcellular compartments. Blocking de novo translation by CHX resulted in 
decrease of some forms of HIF-1 but retention of others, suggesting active 
translocation/degradation pathways were presented in these compartments. Interestingly, 
the short-lived OS-9 was present in all compartments except for the cytosol, and an 
additional band with slower mobility and insensitive to CHX treatment was present in the 
nucleus fraction, which could suggest a novel modification of OS-9.  
 
OS-9 compartmentalized HIF-1 in vesicles from ER 
In addition to our subcellular separation approach, we performed confocal microscopic 
analysis for locating of OS-9 and HIF-1. We first confirmed that over-expression of OS-
9 in HeLa cells displayed the same strong perinuclear reticulum pattern (Fig. 3-4A) as 
reported in the literature (Christianson, Shaler et al. 2008). Only a basal level of HIF-1 
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signal was observed with co-expression of FLAG-OS-9 and HA-HIF-1 which was 
consistent with our data in Figure 3-1B that OS-9 could promote over-expressed HIF-1 
degradation. The basal HIF-1 signal was presented in the nucleus as well as in the 
cytosol where FLAG-OS-9 resided (Fig. 3-4B). Upon treating cells with MG132 to block 
HIF-1 degradation, a strengthened HIF-1 signal was observed in both nucleus and 
cytosol where HIF-1 appeared to be surrounded by the FLAG-OS-9 (Fig. 3-4C). We 
then further examined the subcellular localization of co-expressed HA-HIF-1 and SP, 
as our previous data in Figure 3-1C suggested that SP promoted HIF-1 accumulation. 
Interestingly, a significant amount of HA-HIF-1 was accumulated in a large vesicle in 
the cell and SP was apparently colocalized on the membrane of the vesicle (Fig.3-
4D1&2). Further examination revealed that these vesicles contained proteins from ER 
membrane, such as CNX, suggesting that they were either a malformation of ER or 
aroused from the ER but not Golgi Apparatus (Fig. 3-4E&F). Further testing of other 
OS-9 deletions revealed that GBS, the deletion of glucosidase II beta subunit-like 
protein domain, also displayed similar phenotypes of vesicles that colocalized with CNX, 
suggesting OS-9 associated ERAD may be involved in vesicle cargo formation and 
cycling (Fig. 3-4G&H).  
 
Over-expression of OS-9 had no effect on endogenous HIF-1 function 
Exogenously expressed proteins are less properly folded and those misfolded proteins 
will be refolded or disposed by the PQCS. To investigate whether OS-9 gain-of-function 
affects endogenous HIF-1 stability and function, we established an OS-9 doxycycline 
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(DOX) inducible cell line. OS-9 was highly expressed after 48 hours of Dox treatment 
(Fig. 3-5A). However, over-expression of OS-9 didn’t affect endogenous HIF-1 protein 
level at 1% Oxygen condition (Fig.3-5B). Using quantitative real-time RT-PCR to test 
HIF-1 transactivation activity further demonstrated that over-expression of OS-9 had a 
no effect on HIF-1 mRNA level as well as its target genes expression (Fig. 3-5C). These 
results suggest that OS-9 targets improperly folded HIF-1 for degradation, but not 
properly folding endogenous HIF-1.  
 
OS-9 loss-of-function impedes HIF-1 ubiquitination and prevents inhibition of 
HIF-1 transactivation activity by ER-stress inducer tunicamycin 
Our next aim is to examine whether OS-9 loss-of-function affects HIF-1 stability and 
function. We used a set of siRNAs to target mRNAs of either OS-9.1 or both OS-9.1 & 
OS-9.2 isoforms. Compared to random siRNA control, OS-9 mRNA levels were 
significantly decreased as demonstrated by quantitative real-time RT-PCR assays in both 
normoxia and hypoxia conditions (Fig. 3-6A). Corresponding OS-9 protein levels were 
also significantly decreased. HIF-1 protein levels, however, remained unchanged in 
hypoxic condition by comparison with the random siRNA control. Inhibition of 
proteasome function by MG132 accumulated more poly-ubiquitinated HIF-1 in controls 
than those with OS-9 knocked down, suggesting that OS-9 may facilitate poly-
ubiquitination of HIF-1 for degradation (Fig.3-6B).      
 
Using quantitative real-time RT-PCR to test HIF-1 transactivation activity further 
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demonstrated that knockdown of OS-9 had minor effects on expression of HIF-1 target 
genes under hypoxia condition. Comparing the mRNA levels of three HIF-1 targeted 
genes in OS-9 knock down VS. control, the mRNA levels of CA9 and VEGF were 
decreased, and the mRNA levels of Glut1 remained unchanged (Fig. 6C). We had 
observed that the ER-stress inducer, tunicamycin, can inhibit HIF-1 transactivating 
activity (Fig. 3-6D) by an unknown mechanism. So we used tunicamycin to create a 
stress condition to examine whether knocking down of OS-9 affects HIF-1 function 
under the stress condition. Comparing to the control, the inhibitory effect by tunicamycin 
on three tested HIF-1 target genes were repressed by OS-9 knockdown. Moreover, the 
mRNA levels of both VEGF and GLUT1 from OS-9 knock down and treatment with 
tunicaymcin were even higher than that in non-treated controls (Fig. 3-6E). The above 
results suggest that repression of HIF-1 by tunicamycin is mediated by the OS-9.      
 
Discussion 
In this paper, we demonstrated that OS-9 negatively regulates HIF-1 in the ER through 
the ER quality control system. Limited published data on OS-9 in the last ten years were 
discrepancy. OS-9 was reported to promote HIF-1 degradation by prolyl hydroxylation 
through interacting with HIF-1 and PHDs (Baek, Mahon et al. 2005). A recent paper 
indicated that due to the deficiency of physical interaction of PHD2 and OS-9, OS-9 
plays no direct role in regulation of HIF-1 and O2 homeostasis (Brockmeier, Platzek et 
al. 2011). OS-9 was also described as an ER membranes protein that exposed to the 
cytoplasm for ER-to-Golgi transport of meprin beta (Litovchick, Friedmann et al. 2002). 
Accumulating data in recent years, however, suggested that OS-9, similar to its yeast 
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counterpart Yos9p, is an ER luminal protein that is engaged in the ER-associated protein 
degradation of glycoprotein in the membrane and secretory pathways (Buschhorn, 
Kostova et al. 2004; Bhamidipati, Denic et al. 2005; Kim, Spear et al. 2005; Denic, Quan 
et al. 2006; Gauss, Jarosch et al. 2006; Kanehara, Kawaguchi et al. 2007; Wang, Fu et al. 
2007; Christianson, Shaler et al. 2008; Alcock and Swanton 2009; Hosokawa, Kamiya et 
al. 2009; Bernasconi, Galli et al. 2010; Hosokawa, Kamiya et al. 2010; Mikami, 
Yamaguchi et al. 2010; Satoh, Chen et al. 2010). Unlike Yos9p, which shares only 15% 
similarity with OS-9 primary structure, OS-9 also lacks a C-terminal KDEL ER lumen 
retention sequence. Moreover, motif scanning has revealed a nuclear localization signal 
and an importin beta N-terminal domain profile domain on OS-9, together with the strong 
perinuclear localization profile suggesting that OS-9 may serve a broader role than an ER 
lumen lectin like protein targets only glycoproteins for membrane and secretory pathway.        
 
 
Based on our results, we postulate a model for OS-9 associated degradation of HIF-1, 
but not limited to HIF-1 Fig. 3-7. OS-9 may facilitate protein degradation by trapping 
targeted substrates in the ER supported by other ER-resident components of the ERAD, 
such as Bip. Binding of OS-9 with substrates and other ERAD components further 
promotes the formation of vesicle-like cargos for degradation by proteasomes or endo-
lysosomal proteases. The formation of vesicle may require coating with the non lipidated 
LC3/Atg8 autophagy marker through an autophagy independent pathway. Because we 
have observed that over expression of LC3 can promote OS-9 degradation (data not 
shown). OS-9 and substrates containing vesicle buds out from the ER membrane and 
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transforms to be a degradation body where substrates are subjected to digestion and OS-9 
itself may be cleared in this process as according to the observation in Figure 3-3C&D 
that unlike other ER resident protein, such as calnexin and GRP94, OS-9 has a rapid 
turnover rate. Malfunction of OS-9 such as deletion of GBS domain may disrupt its 
interaction with its ERAD cofactors and result in enlarged vesicles and delayed cycling. 
Although lack of signal peptide prevents SP localizing in the ER lumen, its binding 
domain can still bind to the cytosolic face of its ERAD cofactors that are embedded on 
the ER membrane. Binding of SP somehow impedes vesicle budding and transporting. 
It may also prevent substrates retrotranslocate to the cytosol for degradation.  
 
Although our data have demonstrated that HIF-1 localizes in multiple subcellular 
compartments with distinct post-translational modifications, further studies are needed to 
clarify their roles in regulation of oxygen homeostasis. One possibility suggested by the 
present work is that OS-9 associated ERAD pathway may provide a cleavage form of 
HIF-1 with dominant negative effect on HIF-1 function. Knocking down of OS-9 may 
prevent its formation, and tunicamcyin, however, may have an opposite effect that 
accelerates its formation or prevents its removal. Under normoxia condition, HIF-1 is 
constantly degraded and this dominant negative form may be simultaneously formed and 
protects hypoxia response genes from activation by basal level HIF-1. Actually in some 
types of cells with a robust hypoxic response, such as some renal originated cells, for 
example renal proximal tubule epithelial cells (RPTECs) and RCC4-T314 (VHL+) cells,   
even under normoxia condition, a strong basal level of HIF-1 can be detected, which 
could weaken its response to hypoxia (Chi, Wang et al. 2006). But with the help of 
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dominant negative form of HIF-1 the negative effect of basal level of HIF-1 is reduced, 
and the silence of hypoxia response genes can be maintained. Under hypoxia condition, 
however, with less dominant negative form of HIF-1 formation, and more normal HIF-
1 accumulation, a robust hypoxia response can therefore be achieved. 
 
Together, our data implicate a novel mechanism of HIF-1 regulation, resolve the 
discrepance in previous publications, connect HIF-1 with the ER quality control system, 
expand our understanding of HIF-1 regulatory network as well as ER quality control 
system, and provide a new view of nuclear protein quality control.   
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Figure 3-1 
 
 
 
 
 
 
 
Fig. 3-1. ER localization signal is essential for OS-9 promoted HIF-1 degradation. 
A. Domain architecture of OS-9. Conserved SP, GBS, N-glycosylation site at aa177, ED-
rich domain, nuclear localication signal (NLS) and importin beta N-terminal domain 
profile (IND). B. Human Hep3B cells were transfected with expression vector encoding 
FLAG-tagged OS-9 or EV or anti-sense OS-9 with GAL4-tagged truncated (740-826) 
HIF-1 and were treated with MG132 or vehicle. Western blotting was performed with 
anti-HIF-1and anti-OS-9 antibodies  
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Figure 3-1C 
 
 
 
 
 
 
Fig.3-1C. ER localization signal is essential for OS-9 promoted HIF-1 degradation. 
Human Hep3B cells were transfected with expression vector encoding FLAG-tagged. 
OS-9, or its deletions (SP, NLS, and IND) or EV or anti-sense OS-9 with GAL4-
tagged truncated (740-826) HIF-1 and were treated with MG132 or vehicle. Western 
blotting was performed with anti-HIF-1anti-FLAG and anti--tubulin antibodies. 
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Figure 3-2A&B 
 
 
 
 
 
 
Fig. 3-2A&B. OS-9 physically interacts with HIF-1A. Hep3B cells were transfected 
with expression vector encoding FLAG-tagged OS-9 or EV or anti-sense OS-9 with HA-
tagged full length HIF-1Whole cell lysates (WCL) were prepared in 
immunoprecipitation (IP) buffer, and IP was performed by using anti-FLAG or anti-OS-9 
antibodies and pulled down with Protein G agarose gel.  
Western blotting was performed with anti-HIF-1and anti-OS-9 or anti-FLAG 
antibodies. B. Hep3B cells were transfected with expression vector encoding FLAG-
tagged OS-9 or EV or its deletion form SP and were treated with MG132+DFX+TSA or 
vehicle. Whole cell lysates (WCL) were prepared in immunoprecipitation (IP) buffer, and 
IP was performed by using anti-FLAG antibodies and pulled down with Protein G 
agarose gel. Western blotting was performed with anti-HIF-1and anti-FLAG antibodies.  
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Figure 3-2C 
 
 
 
 
 
 
Fig. 3-2C. OS-9 physically interacts with HIF-1C. Hep3B cells were treated with 
MG132 or MG132+TSA or vehicle and were exposed to 1% or 21% O2 for 6 h. Whole 
cell lysates (WCL) were prepared in immunoprecipitation (IP) buffer, and IP was 
performed by using anti-OS-9 antibodies and pulled down with Protein G agarose gel. 
Western blotting was performed with anti-HIF-1and anti-OS-9 antibodies. 
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Figure 3-3A&B 
 
 
 
 
Fig. 3-3A&B. Multiple forms of HIF-1 are localized in distinct subcellular 
compartments where OS-9 presents. A. The subcellular compartments were separated 
from Hep3B cell treated with MG132+DFX by using method 1. Whole cell lysate and 
protein fractions from cytosol (C), membrane and organelle (M&O), and nucleus (N), 
were analyzed using anti-HIF-1, anti-OS-9, anti-GRP94, anti-CNX and anti-Histone-3 
antibodies. B. The subcellular compartments were separated from Hep3B cells treated 
with MG132+DFX by using method 2. Whole cell lysate and protein fractions from 
cytosol (C), ER membrane (M), and ER lumen (L), were analyzed using anti-OS-9, anti-
GRP94, and anti-CNX antibodies.  
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Figure 3-3C&D 
 
 
 
Fig. 3-3C&D. Multiple forms of HIF-1 are localized in distinct subcellular 
compartments where OS-9 is present. C. RCC4 (VHL-) cells treated with CHX or 
MG132 or vehicle, and WCL were analyzed by using anti-HIF-1, anti-OS-9, anti-
GRP94, anti-CNX and anti--tubulin antibodies. D. The subcellular compartments were 
separated from RCC4 (VHL-) cells treated with CHX or vehicle by using method 2. 
Protein fractions from cytosol (C), ER membrane (M), ER lumen (L) and nucleus (N), 
were analyzed using anti-HIF-1, anti-OS-9, anti-GRP94, anti-PDI, anti-CNX and anti-
IRE1 antibodies. 
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Figure 3-4A 
 
 
 
 
 
Fig. 3-4A. OS-9 compartmentalized HIF-1 in vesicles from the ER. A. 
Immunofluorescence showing co-localization between ectopically expressed OS-9 and 
ER-resident proteins, CNX, GRP94.and Golgi Apparatus resident protein Giantin. HeLa 
cells were transfected with vector expressing FLAG-OS-9 and fixed in paraformaldehyde 
and decorated with anti-FLAG, anti-CNX, anti-GRP94 and anti-Giantin antibodies. 
Staining was performed with AlexaFluor 488 goat anti-rabbit and AlexaFluor 633 goat 
anti-mouse secondary antibodies. The position of the nuclei was visualized by DAPI 
staining.  
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Figure 3-4B 
 
 
 
 
 
Fig. 3-4B. OS-9 compartmentalized HIF-1 in vesicles from ER. B. 
Immunofluorescence showing co-localization between ectopically expressed OS-9 and 
HIF-1. HeLa cells were co-transfected with vectors expressing FLAG-OS-9 and HA-
HIF-1 and fixed in paraformaldehyde and decorated with anti-FLAG and anti-HIF-1 
antibodies. Staining was performed with AlexaFluor 488 goat anti-rabbit and AlexaFluor 
633 goat anti-mouse secondary antibodies. The position of the nuclei was visualized by 
DAPI staining.  
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Figure 3-4C 
 
 
 
 
 
Fig. 3-4C. OS-9 compartmentalized HIF-1 in vesicles from ER. C. 
Immunofluorescence showing co-localization between ectopically expressed OS-9 and 
HIF-1 HeLa cells were co-transfected with vectors expressing FLAG-OS-9 and HA-
HIF-1 and were treated with MG132, and fixed in paraformaldehyde and decorated with 
anti-FLAG and anti-HIF-1 antibodies. Staining was performed with AlexaFluor 488 
goat anti-rabbit and AlexaFluor 633 goat anti-mouse secondary antibodies. The position 
of the nuclei was visualized by DAPI staining.  
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Figure 3-4D1 
 
 
 
 
 
Fig. 3-4D1. OS-9 compartmentalized HIF-1 in vesicles from ER. D. 
Immunofluorescence showing co-localization between ectopically expressed SP and 
HIF-1 HeLa cells were co-transfected with vectors expressing FLAG-SP and HA-
HIF-1 and fixed in paraformaldehyde and decorated with anti-FLAG and anti-HIF-1 
antibodies. Staining was performed with AlexaFluor 488 goat anti-rabbit and AlexaFluor 
633 goat anti-mouse secondary antibodies. The position of the nuclei was visualized by 
DAPI staining. This structure represents 55.6% of HIF-1 positive cells. 
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Figure 3-4D2 
 
 
 
 
 
 
 
Fig. 3-4D2. OS-9 compartmentalized HIF-1 in vesicles from ER. D. 
Immunofluorescence showing co-localization between ectopically expressed SP and 
HIF-1 HeLa cells were co-transfected with vectors expressing FLAG-SP and HA-
HIF-1 and fixed in paraformaldehyde and decorated with anti-FLAG and anti-HIF-1 
antibodies. Staining was performed with AlexaFluor 488 goat anti-rabbit and AlexaFluor 
633 goat anti-mouse secondary antibodies. The position of the nuclei was visualized by 
DAPI staining. This structure represents 40.7% of all HIF-1 positive cells. 
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Figure 3-4E 
 
 
 
 
Fig. 3-4E. OS-9 compartmentalized HIF-1 in vesicles from ER. E. 
Immunofluorescence showing co-localization between ectopically expressed SP and 
HIF-1 HeLa cells were co-transfected with vectors expressing FLAG-SP and HA-
HIF-1 and fixed in paraformaldehyde and incubated with anti-FLAG and anti-CNX 
antibodies. Staining was performed with AlexaFluor 488 goat anti-rabbit and AlexaFluor 
633 goat anti-mouse secondary antibodies. The position of the nuclei was visualized by 
DAPI staining.  
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Figure 3-4F 
 
 
 
 
Fig. 3-4F. OS-9 compartmentalized HIF-1 in vesicles from ER. F. 
Immunofluorescence showing co-localization between ectopically expressed SP and 
HIF-1 HeLa cells were co-transfected with vectors expressing FLAG-SP and HA-
HIF-1 and fixed in paraformaldehyde and decorated with anti-FLAG and anti-Gaintin 
antibodies. Staining was performed with AlexaFluor 488 goat anti-rabbit and AlexaFluor 
633 goat anti-mouse secondary antibodies. The position of the nuclei was visualized by 
DAPI staining.  
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Figure 3-4G 
 
 
 
 
 
Fig. 3-4G. OS-9 compartmentalized HIF-1 in vesicles from ER. H. 
Immunofluorescence showing co-localization between ectopically expressed GBS and 
HIF-1 HeLa cells were transfected with vectors expressing FLAG-GBS and fixed in 
paraformaldehyde and decorated with anti-FLAG and anti- HIF-1 antibodies. Staining 
was performed with AlexaFluor 488 goat anti-rabbit and AlexaFluor 633 goat anti-mouse 
secondary antibodies. The position of the nuclei was visualized by DAPI staining. 
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Figure 3-4H 
 
 
 
 
Fig. 3-4H. OS-9 compartmentalized HIF-1 in vesicles from ER. H. 
Immunofluorescence showing co-localization between ectopically expressed GBS and 
CNX HeLa cells were transfected with vectors expressing FLAG-GBS and fixed in 
paraformaldehyde and decorated with anti-FLAG and anti-CNX antibodies. Staining was 
performed with AlexaFluor 488 goat anti-rabbit and AlexaFluor 633 goat anti-mouse 
secondary antibodies. The position of the nuclei was visualized by DAPI staining. 
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Figure 3-5A&B 
 
 
 
 
Fig. 3-5A&B. Over-expression of OS-9 had no effect on endogenous HIF-
1function. A. The OS-9 tet-on HeLa cells were test on response to HA-OS-9 
expression by DOX induction. Cells were treated with DOX or vehicle for 24 or 48 h. 
Western blotting analysis was carried out with anti-OS-9 and anti-ERp57 antibodies. B. 
The OS-9 tet-on HeLa cells were treated with DOX or vehicle for 48 h and then exposed 
to 1% or 21% O2. Western blotting analysis was carried out with anti-HIF-1 and anti--
tubulin antibodies.  
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Figure 3-5C 
 
 
 
Fig. 3-5C. Over-expression of OS-9 had no effect on endogenous HIF-1function. 
C. The OS-9 tet-on HeLa cells were treated with DOX or vehicle for 48 h and then 
exposed to 1% or 21% O2. Total mRNA was isolated and the mRNA expressions of HIF-
1, CA9, VEGF, GLUT1 and -Actin was analyzed by RT-PCR. 
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Figure 3-6A 
 
 
 
 
Fig. 3-6A. OS-9 loss-of-function impedes HIF-1 ubiquitination and prevents 
inhibition of HIF-1 transactivation activity by ER-stress inducer tunicamycin. A. 
Hep3B cells were transfected with siRNA targeting OS-9.1 or OS-9.1&2 or vehicle and 
were exposed at 1% O2 or 21% O2. The mRNA level of OS-9 was analyzed by real-time 
quantitative RT-PCR. 
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Figure 3-6B  
 
 
 
 
Fig. 3-6B. OS-9 loss-of-function impedes HIF-1 ubiquitination and prevents 
inhibition of HIF-1 transactivation activity by ER-stress inducer tunicamycin. B. 
Hep3B cells were transfected with siRNA targeting OS-9.1 or OS-9.1&2 or vehicle and 
were exposed at 1% O2 or 21% O2 and were treated with MG132. Protein expressions 
were analyzed by western blotting using anti-HIF-1, anti-OS-9 and anti--tubulin 
antibodies. 
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Figure 3-6C  
 
 
 
 
 
 
Fig. 3-6C. Knock down of OS-9 impedes HIF-1 ubiquitination and prevents 
inhibition of HIF-1 transactivation activity by ER-stress inducer tunicamycin. 
C. Hep3B cells were transfected with siRNA targeting OS-9.1 or OS-9.1&2 or vehicle 
and were exposed at 1% O2 or 21% O2. The mRNA level of CA9, VEGF and GLUT1 
were analyzed by real-time quantitative RT-PCR.  
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Figure 3-6D 
 
 
 
 
Fig. 3-6D. OS-9 loss-of-function impedes HIF-1 ubiquitination and prevents 
inhibition of HIF-1 transactivation activity by ER-stress inducer tunicamycin. D. 
Hep3B cells were treated with tunicamycin or vehicle and were exposed at 1% O2 or 
21% O2. The mRNA level of CA9, VEGF and GLUT1 were analyzed by real-time 
quantitative RT-PCR.  
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Figure 3-6E 
 
 
 
Fig. 3-6E. OS-9 loss-of-function impedes HIF-1 ubiquitination and prevents 
inhibition of HIF-1 transactivation activity by ER-stress inducer tunicamycin. E. 
Hep3B cells were transfected with siRNA targeting OS-9.1 or OS-9.1&2 or vehicle and 
were treated with tunicamycin or vehicle and exposed at 1% O2 or 21% O2. The mRNA 
level of CA9, VEGF and GLUT1 were analyzed by real-time quantitative RT-PCR. 
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Figure 3-7 
 
 
 
 
Fig. 3-7. A model for OS-9 associated degradation of HIF-1Nascent HIF-1 or 
misfolded HIF-1 or HIF-1 need to be transported through the nuclear envelop is 
subject to quality control by ER quality control system by direct interaction with OS-9. 
Binding with OS-9 subsequently recruits other ERAD cofactors, such as Bip to form a 
protein complex. Accumulation of these protein complexes induce ER membrane 
banding and forming a vesicle that buds out from the ER and transports into the cytosol. 
This vesicle is further recognized by other cytosolic factors and HIF-1 as well as OS-9 
is degraded by proteasomes or endo-lysosomal proteases. 
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Chapter 4: Tunicamycin Induces Ubiquitination-Independent Degradation of HIF-
1 and Overcomes HIF-Associated Resistance to Doxorubicin 
 
Abstract 
Hypoxia-inducible factor 1 (HIF-1) is a master regulator of oxygen homeostasis and 
glucose metabolism. HIF-1 activation reprograms cellular metabolism, promotes cell 
survival and facilitates cellular adaptation to stresses caused by radiation or 
chemotherapy, which collectively contribute to resistance to therapies. Tunicamycin, an 
antibiotic that inhibits N-linked glycosylation, has been shown to possess therapeutic 
effect in cancer therapy. However, the biochemical and molecular mechanisms 
underlying its pharmacological effect remain elusive. Here, we present data to show that 
tunicamycin destabilizes HIF-1the functional determining subunit of HIF-1, by a 
ubiquitination-independent, but proteasome-dependent mechanism. We also show that 
physiologically relevant doses of tumicamycin are sufficient to suppress HIF-1 function 
in several tumor cell lines. Particularly, we show that hypoxia-induced drug resistance to 
doxorubicin in renal carcinoma cells can be overcome by tunicamycin. These findings 
indicate that tunicamycin may serve as a HIF-1 inhibitor to sensitize hypoxic cancer cells 
to chemotherapy. Our data also suggest that protein glycosylation, an endoplasmic 
reticulum associated function, is involved in the regulation of HIF-1 stability and 
function. 
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Introduction 
The central challenges in oncology are tumor progression and resistance to therapy. 
Increasing evidences suggest that hypoxia contributes to both challenges through cellular 
adaptations to the oxygen deficient tumor microenvironment by promoting cell survival, 
motility, and tumor angiogenesis (Wilson and Hay 2011). Tumor hypoxia is considered 
the best validated target for cancer therapy. Hypoxia-inducible factor 1(HIF-1), the 
master player in oxygen homeostasis, regulates a variety of genes that are responsible for 
the hypoxic adaptations (Harris 2002; Le and Giaccia 2003). Therefore, blocking hypoxic 
adaptation by inhibition of HIF-1 function provides promising strategies in tumor 
therapy.  
 
The HIF-1 transcriptional factor complex consists of two subunits. The  subunit (HIF-
1) is highly regulated in an oxygen dependent manner, where at normoxic condition the 
constitutively transcribed and translated HIF-1 is rapidly degraded by ubiquitination-
proteasomal system (Salceda and Caro 1997; Huang, Gu et al. 1998; Kallio, Wilson et al. 
1999; Kamura, Sato et al. 2000). This process is mediated firstly by hydroxylation of 
prolyl residues in the conserved oxygen-dependent degradation domain of de novo 
translated HIF-1 by the oxygen, iron, and oxoglutarate dependent prolyl-hydroxylase 
enzymes and then recruitment of the von Hippel-Lindau (VHL) protein, a tumor 
suppressor that serve as a part of E3 ubiquitin ligase complex, which eventually leads to 
ubiquitination of HIF-1 and degradation at 26S proteasome (Maxwell, Wiesener et al. 
1999; Cockman, Masson et al. 2000).   
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In addition to oxygen-dependent VHL associated ubiquitination-proteasomal regulation, 
there are multiple regulatory mechanisms control the levels of HIF-1 as well as its 
transcriptional activity. In the last few years, intense investigation and efforts has been 
focused on identification of HIF-1 inhibitors.  Several categories of inhibitors that target 
to different HIF-1 regulatory pathways have been identified (Belozerov and Van Meir 
2005). For example, histone deacetylase inhibitors (HDACs) have been reported to 
inhibit HIF-1 expression through a pathway by affecting HSP70/HSP90 chaperone axis 
and inducing HIF-1 ubiquitin-independent proteasomal degradation (Fath, Kong et al. 
2006; Kong, Lin et al. 2006).  
 
Tunicamycin, an antibiotic that inhibits the first step of N-linked glycosylation, has been 
suggested a therapeutic potential in cancer therapy, whereas it enhances radiosensitivity 
and chemosensitization of wide variety of tumor cells (Takahashi, Iwahori et al. 1997; 
Miyake, Hara et al. 2000; Shiraishi, Yoshida et al. 2005; Ling, Li et al. 2009; Huong, 
Moon et al. 2011). However, whether tunicamycin affects hypoxia pathway has never 
been examined. In this study, we present evidence for the first time that tunicamycin 
inhibits HIF-1 function by a pathway that does not involve VHL, or HSP70 and is 
independent on ubiquitination but requires proteasome. Furthermore, we utilized RCC4 
(VHL-) and RCC4-T314 (VHL+) cells as models to investigate the effects of 
tunicamcyin on cell survival by combination treatment with doxorubicin, a drug used in 
cancer chemotherapy, under hypoxic condition or normoxic condition. We further show 
that tunicamycin and doxorubicin have a synergistic effect on hypoxia responsive RCC4 
(VHL+) cells, but not on hypoxia non-responsive RCC4 (VHL-) cells, which suggested 
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that tunicamycin can be exploited in clinical studies of novel drug combinations with 
doxorubicin targeting tumor hypoxia.  
 
Materials and Methods 
Cell cultures  
Hep3B cells were obtained from the ATCC and cultured according to the 
recommendation from ATCC. RCC4 (VHL-) and RCC4-T314 (VHL+) cells were 
provided by (Maxwell, Wiesener et al. 1999). TS20 cells were kindly provided by Dr. 
Ozer (UMDNJ, New Jersey) (Zeng, Donegan et al. 1984; Lao, Chen et al. 2011). RCC4, 
RCC4-T314 and TS20 cell lines were maintained in DMEM medium supplemented with 
10% fetal bovine serum, L-glutamine (Invitrogen), and mix of other amino acids 
(Mediatech). TS20 cells were maintained at 35°C (permissive temperature). Hypoxia 
(0.5% O2 or 1% O2, 5% CO2) conditions were created by incubating cells in an oxygen 
workstation (In VIVO2; Ruskin Tech). 
 
Chemicals and Reagents 
Tunicamycin (TM) was purchased from Enzo Life Sciences (Cat#: BML-CC104-0010, 
Plymouth Meeting, PA). Proteasome inhibitor MG132 (Z-LLL-CHO), thapsigargin (TG) 
and dithiothreitol (DTT), Doxorubicin hydrochloride (DOX) and Etoposide (ETO) were 
purchased from Sigma. Glycosylation inhibitors swainsonine (SW), castanospermine 
(CA), deoxynojirimycin (DN) and deoxymannojirimycin (DM) are purchased from 
Sigma. 
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Antibodies, Cell Lysate Preparation, and Western Blotting 
Mouse anti--tubulin antibodies were purchased from Sigma-Aldrich (St. Louis, MO). 
Rabbit anti-E1, anti-HIF-1 and anti-Ubiquitin antibodies were from Cell Signaling 
(Beverly, MA), Novus Biologicals (Littleton, CO) and Enzo Life Sciences (Plymouth 
Meeting, PA), respectively. Rabbit anti-HSP70 was purchased from Enzo Life Sciences. 
Horseradish peroxidase-coupled secondary antibodies were from Sigma-Aldrich (St. 
Louis, MO) and Invitrogen (Carlsbad, CA).  
 
For Western blot analyses, the method was as previously described (Lao, Chen et al. 
2011). Briefly, cells were lysed in urea buffer (8 M urea, 10 mM Tris, 10% glycerol, 1% 
SDS, 5 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1 × protease inhibitor 
mix, pH 6.8) on ice with an Ultra-Turrax T8 homogenizer (IKA GmbH & Co.) for 60 s. 
Proteins in the lysates were separated on a 4–15% gradient SDS-PAGE (Bio-Rad), and 
then electrotransferred onto a polyvinylidene difluoride membrane. The membrane was 
processed in subsequent steps: blocking with 5% milk in TBST, incubating with specific 
primary antibody, washing in TBST three times, and incubating with horseradish 
peroxidase-labeled secondary antibody. The membranes were finally developed with the 
ECL Plus system (Amersham Biosciences). 
 
Quantitative RT-PCR (qRT-PCR) 
Hep3B cells, seeded in 6 well plates, were treated as indicated. Total RNA was extracted 
using the Qiagen RNeasy kit. cDNA was synthesized by superscript II reverse 
transcriptase (Invitrogen) with random hexamers as primers. qRT-PCR was performed 
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using Taqman gene expression master mix and StepOnePlus Real-Time PCR System 
(Applied Biosystems). Data were quantitatively analyzed by StepOne software with 
comparative CT method. β-actin was set as endogenous control. Data are presented as 
mean ± SEM. Differences between experiments were analyzed for statistical significance 
(p < 0.05) by student t-tests. 
 
Cell proliferation analysis 
Cells pre-treated with or without tunicamycin (0.5 g/ml) under 0.5% O2 or 21% O2 
condition for 24 hours were plated in triplicate in 96-well plates at a density of 500 
cells/well with doxorubicin (5 M) or etoposide (50 M)  treatment for additional 48 
hours. Cell numbers were examined using the CyQUANT® NF-Cell Proliferation Kit 
(Invitrogen) with reference to standard curve obtained from each of the tested cell lines. 
Data were quantitatively analyzed by student T-test. 
 
Results 
Tunicamycin triggers proteasome-dependent degradation of HIF-1  
We studied the effect of tunicamycin, a glycosylation inhitibor and an ER-stress inducer, 
on HIF-1 levels in response to hypoxia. Fig. 4-1 shows that the tunicamycin inhibits 
HIF-1 expression at 1% O2 condition in Hep3B cells. To further investigate the 
underlying mechanisms of tunicamycin-mediated repression of HIF-1, we tested 
whether this effect required an active proteasome system. Use of MG132, a proteasome 
inhibitor, restored the HIF-1 levels at 1% O2 condition in Hep3B cells (Fig. 4-1B), 
indicating that tunicamycin triggered HIF-1 degradation through the proteasome 
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system. As an ER-stress inducer, tunicamycin has been reported to activate unfolded 
protein response (UPR), and one of the effects of UPR is inhibition of de novo 
translation. To test whether the tunicamycin-mediated repression of HIF-1 is caused by 
inhibition of de novo translation, we measured the rate of HIF-1 accumulation in 
normoxic cells exposed to MG132. Fig. 4-1C shows that tunicamycin did not affect the 
progressive accumulation of HIF-1 in normoxic Hep3B cells exposed to MG132 for up 
to 6 h, suggesting that tunicamycin does not block the de novo translation of HIF-
1These data indicate that tunicamycin suppresses HIF-1 levels by triggering its 
degradation through the proteasome system. 
 
Tunicamycin-induced HIF-1 degradation is ubiqutination-independent 
At normixic condition, HIF-1 is ubiquitinated by VHL complex, an E3 ubiquitin ligase, 
and the poly-ubiqutinated HIF-1 is subsequently degraded by proteasome (Liang, Kong 
et al. 2006). To examine whether tunicamycin-induced HIF-1 degradation depends on 
the ubiquitination process, we first examined the effect of tumicamycin on the poly-
ubiquitinated HIF-1 levels under normoxic conditions. By extending the exposure time 
to increase the detecting sensitivity, we were able to reveal the poly-unbiquitinated and 
non-ubiquitinated HIF-1 in Western blot analysis.  Fig. 4-2A shows that at normoxic 
condition, tunicamycin treatment did not increase the higher molecular weight poly-
ubiquitinated HIF-1 in Hep3B cells. Hypoxia represses the hydroxylation and 
subsequent ubiquitination of HIF-1. Tunicamycin treatment did not restore the HIF-1 
ubiquitination under hypoxia conditions. To further investigate whether the ubiquitination 
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process is involved in tunicamycin-induced degradation of HIF-1 we utilized TS20 
cells, which lack ubiquitination due to the presence of a temperature-sensitive ubiquitin-
activating enzyme, E1 (Lao, Chen et al. 2011). At restrictive temperature, destabilization 
of E1 in these cells leads to inhibition of ubiquitnation and a fast accumulation of HIF-
1, even under normoxic conditions (Salceda and Caro 1997; Lao, Chen et al. 2011). Fig. 
4-2B shows that the accumulation of HIF-1 protein was inhibited by tunicamycin 
treatment in TS20 cells cultured at 39°C. To rule out the possibility that E1 protein was 
stabilized by tunicamycin thus promoting HIF-1ubiquitination, we examined E1 
protein levels and overall ubiquitination profile. Fig. 4-2C shows that tunicamycin did 
not significantly affect the overall ubiquitination levels or E1 protein levels. Inhibition of 
proteasome activity by MG132 blocked tumicamycin-triggered HIF-1 degradation in 
TS20 cells, confirming that tunicamycin induced degradation of HIF-1 is a 
ubiquitination-independent process. 
 
Tunicamycin-induced degradation of HIF-1 is neither VHL- nor HSP70-
dependent  
It has been established that both VHL and CHIP may serve as E3 ligase to regulate HIF-
1 ubiquitination. It has been reported that HSP70 interacts with HIF-1 and facilitates 
the recruitment of CHIP to HSP70 client proteins (Luo, Zhong et al. 2010). To test 
whether tunicamycin-triggered HIF-1 degradation required a functional VHL protein, 
we used VHL-deficient RCC4 cells, which express HIF-1 constitutively, and VHL-
positive RCC4 cells.  Figure 4-3A shows that tunicamycin destabilized HIF-1 in both 
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VHL-positive and negative cells, indicating tumicamycin-triggered HIF-1 degradation 
is independently of VHL function. In TS20 cells, HSP70 was activated and stabilized at 
39°C, which was associated with the accumulation of HIF-1. However, treatment of 
cells with tunicamycin at concentrations as low as 0.1 g/ml effectively decreased, not 
increased HSP70 levels (Fig. 4-3B). Therefore, it is unlikely that tumicamycin triggers 
HIF-1 degradation by enhancing HSP70/CHIP-mediated HIF-1 ubiquitination.  
  
Tunicamycin inhibits HIF-1 function 
To investigate whether tunicamycin inhibits HIF-1 function under hypoxic conditions, 
we measured the relative mRNA levels of several representative HIF-1 target genes, 
including CA9, Glut1 and VEGF in Hep3B cells. Figure 4-4A & B shows that under 
hypoxic conditions tunicamycin significantly repressed CA9 and Glut1 mRNA levels 
(P<0.05). It has been reported that tunicamycin activates VEGF transcription at normoxic 
condition (Abcouwer, Marjon et al. 2002), which was also observed in Figure 4-4C. 
However, at hypoxic conditions, the hypoxia-induced increase of VEGF expression was 
significantly repressed by tunicamycin (P<0.05). These results indicate that tunicamycin 
inhibits HIF-1function. 
 
The effects of other ER-stressors on HIF-1 stability 
Tunicamycin is a well characterized inhibitor of N-linked protein glycosylation. It has 
been known that blocking protein glycosylation accumulates misfolded/unfolded proteins 
in the ER and induces ER-stress, which may in turn lead to unfolded protein response 
(UPR). To test whether tunicamycin-triggered HIF-1 degradation is caused by ER-stress 
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or UPR, we examined the effects of other ER-stressors including thapsigargin (TG) and 
dithiothreitol (DTT) on HIF-1 stability. Thapsigargin blocks the ER calcium ATPase 
pump, resulting in the increase of cytosolic calcium concentration and depletion of ER 
calcium stores (Thastrup, Foder et al. 1987; Jackson, Patterson et al. 1988). DTT is a 
strong reducing agent that disrupts the disulfide bonds of protein hence causing protein 
misfolding (Meienhofer, Czombos et al. 1971; Kaji and Lodish 1993). Fig. 4-5A shows 
that under hypoxic conditions, all of the three types of ER-stressors decreased HIF-1 
levels in Hep3B cells. However, further test in RCC4 (VHL+) cell shows that unlike 
tunicamycin and DTT, thapsigargin increased HIF-1 levels (Fig. 4-5B).  In TS20 cells 
cultured at restrictive temperature, both tunicamycin and thapsigargin repressed HIF-1 
levels while DTT had no apparent effect on HIF-1 stability (Fig. 4-5C). Therefore, 
thapsigargin and DTT affect HIF-1 stability in a cell type specific manner, while 
tunicamycin consistently repressed HIF-1 stability in all different types of cells that we 
have tested. These data indicate ER-stress may not be the direct cause of tunicamycin-
triggered degradation of HIF-1. 
  
Tunicamycin inhibits hypoxia-induced resistance to Doxorubicin 
HIF-1 plays a critical role in promoting cancer cell survival by inducing adaptive 
strategies in response to various stresses including hypoxia and chemotherapy. It has 
been reported that hypoxia induces doxorubicin resistance in many human carcinoma 
cells, such as PC-3, MDA-MB-231 and Du-145 cells (Matthews, Adams et al. 2001; 
Frederiksen, Siemens et al. 2003; Frederiksen, Sullivan et al. 2007). We next examined 
whether hypoxia provided a survival advantage for cells incubated with chemotherapeutic 
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agents. Human RCC4 cells (VHL- and VHL+) were incubated with doxorubicin under 
both normoxic and hypoxic conditions and the cell survival rates were examined. We 
observed that hypoxia significantly increased RCC4-T314 (VHL+) cells' survival in 5 
M of doxorubicin, compared with 21% O2 (Fig. 4-6A).  To determine whether the 
hypoxic enhanced drug resistance is associated with HIF-1 activation, we incubated 
RCC4 (VHL-) cells, which constitutively express HIF-1 under either hypoxic or 
normoxic conditions, with doxorubicin (Maxwell, Wiesener et al. 1999). Data presented 
in Fig 4-6B show that doxorubicin had similar killing effects under normoxic or hypoxic 
condition, indicating hypoxic activation of HIF-1 plays a major role in hypoxia-
associated resistance to doxorubicin.  To further examine whether inhibition of HIF-1 
by tunicamycin could restore the drug-sensitivity of these cells, we pretreated cells with 
tunicamycin at 0.5% O2 condition prior to doxorubicin treatment. Results showed in Fig. 
4-6C indicate that tunicamycin pre-treatment significantly inhibited hypoxia-induced 
resistance to doxorubicin in RCC4 (VHL+) cells.   
 
Discussion 
Hypoxia has been shown to play a critical role in tumor progression and resistance to 
chemo- and radiation therapy in many tumor types. Targeting hypoxia or HIF-1, the 
essential component of hypoxia responsive mechanisms, could prove to be a potent 
mechanism for treating tumors. We have provided evidences that tunicamycin represses 
HIF-1 stability as well as function in an ubiquitination-independent manner and it 
sensitizes hypoxia induced doxorubicin resistance in RCC4-T314 (VHL+) cells. Our 
study suggests that tunicamycin can be used as new strategies to targeting hypoxia tumor.  
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How tunicamycin triggers HIF-1 degradation remains unclear. Tunicamycin inhibits 
protein N-linked glycosylation by blocking of the transfer of N-acetylglucosamine-1-
phosphate from UDP-N-acetylglucosamine to dolichol phosphate in the first step of 
glycoprotein synthesis by DPAGT1 in ER (Heifetz, Keenan et al. 1979; Keller, Boon et 
al. 1979; Brandish, Kimura et al. 1996). Therefore, the presence of tunicamycin results in 
proteins missing N-glycosylation and further causes accumulation of mis- and unfolded 
proteins in the ER lumen (Reiling, Clish et al. 2011). One possibility is inhibition of 
protein glycosylation somehow disrupted the folding and maturation process of HIF-1. 
Previously we reported that histone deacetylase inhibitors and Hsp90 inhibitors caused 
ubiquitination-independent degradation of HIF-1. Considering the role of HSP90 in 
HIF-1 folding maturation, and the inhibitory effect of hyperacetylation on HSP90, we 
proposed a model that misfolded HIF-1 triggers ubiquination-independent degradation 
of HIF-1The tunicamycin triggered ubiquitination-independent HIF-1 degradation 
provides new insight into the proposed quality control system of HIF-1.  
 
An overwhelming load of misfolded proteins also causes ER stress and triggers the 
unfolded protein response (UPR). UPR aims to restore ER homeostasis by multiple 
regulatory pathways including halting protein translation, up-regulation of molecular 
chaperones involved in protein folding, and induction of ER-associated degradation 
(ERAD) (Ron and Walter 2007). It is possible that the tunicamycin-triggered HIF-1 
degradation is processed by ERAD. We tested various compounds that induce ER 
stresses, while other ER stressors show cell type-specific effects on HIF-1 stability, 
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tunicamycin induced HIF-1 degradation in all cell types tested, suggesting that protein 
glycosylation may be the key process for HIF-1 maturation. 
 
Increasing studies demonstrated that ER stress and UPR play a role in altering the 
sensitivity of cancer cells to chemotherapeutic drugs by either enhancing or impeding the 
efficacy of various classes of drugs, which makes predicting the outcomes of treatment 
targeting UPR pathway more complicated (Nawrocki, Carew et al. 2005; Mann and 
Hendershot 2006; Dong, Ni et al. 2008; Kraus, Malenke et al. 2008; Jiang, Mao et al. 
2009; Li, Wang et al. 2009; Zhang, Inukai et al. 2011). Tunicamycin has been explored as 
a cancer therapeutic agent. More studies have explored it as an agent to sensitize tumor 
cells to various drugs including doxorubincin, epirubicin, vincristine, cisplatin, 
camptothecin, etoposide, and proteasome inhibitor-I (Pro-I). A variety of tumors, 
including ovarian cystadenocarcinoma, head-and-neck carcinoma, hepatocellular 
carcinoma, prostate cancer, breast carcinoma, myeloma and B-lymphoid tumor, have 
been tested, resulted in different outcomes (Glassy and Ferrone 1984; Noda, Fujieda et al. 
1999; Delom, Emadali et al. 2007; Hiss, Gabriels et al. 2007; Jiang, Chen et al. 2007; 
Hsu, Chiang et al. 2009).  Data from literature shown that tunicamycin induces resistance 
to etoposide in human hepatocellular carcinoma cells, but sensitizes human ovarian 
cystadenocarcinoma cells to doxorubicin (Hiss, Gabriels et al. 2007; Hsu, Chiang et al. 
2009). In our studies, we have combined tunicamycin with doxorubicin. Our data show 
that tunicamycin sensitizes RCC4 cells to doxorubicin. More importantly, our data links 
the sensitizing effect of tunicamycin to HIF-1 activation, a common phenomenon 
observed in tumors. 
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Etoposide is a DNA repair inhibitor that generally repress the topoisomerase II 
(Guichard, Terret et al. 1999). We also determined the combinatorial effect of 
tunicamycin with etoposide in RCC4 cells. We exposed RCC4 (VHL-) and RCC4 
(VHL+) in 0.5% O2 in the presence or absence of etoposide (50 M). Similar to the 
induction of doxorubicin resistance, hypoxia significantly increased RCC4 (VHL+) cells 
survival in etoposide treatment (Fig. 4-S1). The effects of tunicamycin in hypoxia-
induced resistance to etoposide, however, were different from doxorubicin treatment. 
Tunicamycin promoted both RCC4 (VHL-) and RCC4 (VHL+) cells survival in 
etoposide treated cells, suggesting that etoposide resistance might involve other 
mechanisms rather than, or in addition to tumor hypoxia. These data also suggest that 
doxorubicin and etoposide, though being classified as the same class of drugs, may utilize 
different cellular processes and mechanisms in cancer chemotherapy and resistance.  
 
Renal cell carcinoma (RCC), the most common type of kidney cancer in adult, is highly 
resistant to radiation therapy and chemotherapy (Rini and Atkins 2009). About 80% of 
RCC are associated with loss of VHL protein function which causes constitutively 
expression of HIF-1 and HIF-1 target genes (Clark 2009). In our study, we have used 
RCC4(VHL-) cells in which HIF-1 is constitutively active, and RCC4-T314 (VHL+) 
cells in which HIF-1 is activated by hypoxia to test how combination of tunicamycin with 
doxorubicin or etoposide affects cell survival during hypoxia condition. The data are 
consistent with the observation that tunicamycin represses HIF-1 function, which 
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enhances the doxorubicin-induced cell death in hypoxic RCC4-T314 (VHL+) cells or 
normoxic RCC4 (VHL-) cells. 
 
In summary, our finding indicates that tunicamycin triggers ubiquitination-independent 
degradation of HIF-1 and represses HIF-1 function. Considering HIF-1 activation is a 
critical factor for tumor adaptation to stress and chemoresistance, tunicamycin may serve 
as a HIF-1 inhibitor that sensitizes hypoxic tumors to chemotherapy (Fig. 4-7). 
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Figure 4-1 
 
Fig. 4-1. Tunicamycin triggers proteasome-dependent reduction of HIF-1. A & B: 
Hep3B cells were treated with 2.5g/ml tunicmaycin or MG132 (5 M) at 21% or 1% O2 
condition for 8 hours. Cell lysate were analyzed by Western blotting using anti-HIF-1 
and tubulin antibodies. C: Tunicamycin does not affect HIF-1 translation. Normoxic 
Hep3B cells were exposed to MG132 (5 M) in the presence or absence of Tunicamycin, 
and HIF-1 accumulation was measured at 2, 4 and 6 h. 
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Figure 4-2 
 
 
 
Fig.4-2. Tunicamycin induced HIF-1 degradation is ubiqutination independent. A: 
Hep3b cells were exposed to 1% O2 or 21% O2 and treated with tunicamycin for 6 h. 
Cell lysate were analyzed by Western blotting using anti-HIF-1 and -tubulin 
antibodies. B: TS20 cells were cultured at 35°C or 39°C with tunicamycin treatment. C: 
TS20 cell were treated with tunicamycin in a time course (0, 3, 6 h) at 35°C and 39°C. 
Cell lysates were analyzed by Western blotting using anti-E1, anti-HIF-1, anti-
Ubiquitin and anti--tubulin antibodies. 
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Figure 4-3 
 
 
Fig.4-3. Tunicamycin induced degradation of HIF-1 is VHL- and HSP70-
independent. A: RCC4 (VHL-) and RCC4 (VHL+) cells were exposed to 21% O2 or 1% 
O2 and treated with or without tunicamycin for 6 h. Cell lysate were analyzed by Western 
blotting using anti-HIF-1 and -tubulin antibodies. B: TS20 cell were treated with 
tunicamycin in a dose curve (0, 0.1, 0.5and 2.5 g/ml) at 39°C. Cell lysates were 
analyzed by Western blotting using anti-HSP70, anti-HIF-1 and anti--tubulin 
antibodies. 
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Figure 4-4 
 
 
 
 
Fig.4-4. Tunicamycin inhibits HIF-1 function. A,B&C: Hep3B cells, seeded in 6 
well plates, were treated with or without tunicamycin. Total RNA was extracted and 
cDNA was synthesized with random hexamers as primers. qRT-PCR was performed to 
test three HIF-1 target genes  (CA9, VEGF, and GLUT1) mRNA levels. Data were 
quantitatively analyzed with comparative CT method. β-actin was set as endogenous 
control.  
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Figure 4-5 
 
 
 
 
Fig.4-5. The effects of other ER-stressors on HIF-1 stability A&b : Hep3b cells and 
RCC4 (VHL+) cells were exposed to 1% O2 or 21% O2 and treated with or without 
tunicamycin, thapsigargin (TG, 300nM) and dithiothreitol (DTT, 500M ) for 6 h. Cell 
lysate were analyzed by Western blotting using anti-HIF-1 and -tubulin antibodies. C: 
TS20 cells were cultured at 39°C with tunicamycin, TG, and DTT treatment. Cell lysates 
were analyzed by Western blotting using anti-HIF-1 and anti--tubulin antibodies. D: 
TS20 cells were treated with tunicamycin and TG together with MG132. Cell lysates 
were analyzed by Western blotting using anti-HIF-1 and anti--tubulin antibodies. 
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Figure 4-6A&B 
 
 
 
 
 
 
Figure 4-6A&B. Tunicamycin inhibits hypoxia-induced resistance to Doxorubicin 
Cells were cultured and treated under specified conditions and cell numbers were 
examined using the CyQUANT® NF-Cell Proliferation Kit (Invitrogen) with reference to 
standard curve obtained from each of the tested cell lines. Data were quantitatively 
analyzed by student T-test. Significant changes were marked (p≤0.05) with “*”. A and B. 
RCC4-T314 (VHL+) and RCC4(VHL-) cells were plated in triplicate in 96-well plates at 
a density of 500 cells/well, cultured under 0.5% O2 or 21% O2 conditions for 24 hours, 
and treated with doxorubincin (DOX, 5 M) for additional 48 hours.  
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Figure 4-6C&D 
 
 
 
 
 
 
Figure 4-6C&D. Tunicamycin inhibits hypoxia-induced resistance to Doxorubicin 
C. RCC4-T314 (VHL+) cells pre-treated with or without tunicamycin (0.5 g/ml) under 
0.5% O2 condition for 24 hours, plated in triplicate in 96-well plates at a density of 500 
cells/well with doxorubincin (DOX, 5 M) for additional 48 hours. D. RCC4(VHL-) cells 
pre-treated with or without tunicamycin (0.5 5 g/ml) under 21% O2 condition 
for 24 hours, plated in triplicate in 96-well plates at a density of 500 cells/well with 
doxorubincin (DOX, 5 5 M) for additional 48 hours. 
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Figure 4-7 
 
 
 
 
 
Fig. 4-7. Schematic representation of the mechanisms that tunicamycin inhibits 
hypoxia induced chemoresistance through repression of HIF-1. Tumor cells under 
treatment with chemotherapeutic drug such as doxorubicin are progressing to death, 
however, at hypoxia condition, HIF-1a induces hypoxic adaptations which render tumor 
cells chemoresistantce and promote cell survival. Tunicamycin represses HIF-1a function 
thus diminishes hypoxic adaptation and prevents cells from death. 
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Figure 4-S1 
 
 
 
 
 
 
Fig.4-S1. Tunicamycin inhibits hypoxia induced resistance to Doxorubicin 
Both RCC4 (VHL-) and RCC4-T314 (VHL+) Cells pre-treated with or without 
tunicamycin (0.5g/ml) under 0.5% O2 or 21% O2 condition for 24 hours were plated in 
triplicate in 96-well plates at a density of 500 cells/well with doxorubincin (DOX, 5M) 
treatment for additional 48 hours. Cell numbers were examined using the CyQUANT® 
NF-Cell Proliferation Kit (Invitrogen) with reference to standard curve obtained from 
each of the tested cell lines. Data were quantitatively analyzed by student T-test. *≤0.05 
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Chapter 5: Discussion and Conclusion  
Hypoxia inducible factors (HIF-1 and HIF-2) are potential therapeutic targets for both 
cancer and ischemic disorders, particularly for hypoxic and angiogenic tumors that are 
usually resistant to traditional radiation and chemotherapy (Koukourakis, Simopoulos et 
al. 2003; Hewitson and Schofield 2004; Monsef, Helczynski et al. 2007; Ban, Uto et al. 
2011). Blocking tumor angiogenesis has been extensively explored as a novel treatment 
for cancers for the past decade. The identification of HIF-1, 2 as master regulators of 
multiple adaptive pathways and the complete dissection of the conventional regulatory 
mechanisms of HIF function make it possible to modulate HIF-1, 2 as a better alternative 
to current angiogensis-based therapies that generally target one or two angiogenic 
signaling pathways. HIF function also promotes cell survival and proliferation under 
adverse environments such as exposure to hypoxia/ischemia, radiation and 
chemotherapeutics, adding additional rationale to repress HIF function as an independent 
therapy or as part of combined regimen.  
In addition to HIF inhibitors identified by the compound screening processes (Narita, Yin 
et al. 2009; Xia, Bi et al. 2009; Yewalkar, Deore et al. 2010; Xia, Jin et al. 2011), basic 
research and clinical trials have shown that several classes of structurally distinct new 
anti-cancer, small molecular weight compounds, including histone deacetylase (HDAC) 
inhibitors (HDACs) (Fath, Kong et al. 2006; Liang, Kong et al. 2006), heat shock protein 
(Hsp) 90 inhibitors (Vastag 2006; Kurashina, Ohyashiki et al. 2009), compounds 
disturbing microtubule dynamics (DMD) (Jung, Isaacs et al. 2003; Salama, Kamel et al. 
2009; Carbonaro, O'Brate et al. 2011), and proteasomeal inhibitors (PSIs)(Richardson, 
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Hideshima et al. 2003; Williams, Pettaway et al. 2003; Boccadoro, Morgan et al. 2005; 
Newcomb, Ali et al. 2005; Veschini, Belloni et al. 2007) block angiogensis and suppress 
tumor growth, at least in part, through repressing HIF function. Since these compounds 
were not originally designed to target HIF, the unexpected convergence suggests that a 
basic multi-component system is required for HIF function.  
Particularly, in this study we have found that Tunicamycin, an ER-stress inducer and 
glycosilation inhibitor, trigger HIF-1 degradation independently of VHL-mediated 
ubiquitination. We further demonstrate that hypoxia induced doxorubicin resistance in 
renal carcinoma cells is reduced by tunicamycin treatment, indicating that tunicamycin 
may serve as a HIF-1 inhibitor that sensitizes cells to tumor therapy by inhibition of 
hypoxic adaptation in tumor cells.  The way that tunicamycin represses the 
transactivation potential of HIF-1 is similar to that HDACIs and Hsp 90 inhibitors 
imposed on HIF-1(Neckers 2002; Han, Oh et al. 2005; Alqawi, Moghaddas et al. 2006; 
Liu and Semenza 2007; Xiong, Zhao et al. 2009; Chen and Sang 2011; Geng, Harvey et 
al. 2011; Park, Kim et al. 2011). Both Hsp 90 and Hsp 70 have been found to interact 
with HIF-1. Hsp 90, Hsp70 and their associated cofactors are the molecular chaperones 
that bind and stabilized proteins at intermediate stages of folding, assembly, translocation 
and degradation (Katschinski, Le et al. 2004; Genin, Hasdai et al. 2008; Nikinmaa, 
Leveelahti et al. 2008; Barliya, Mandel et al. 2011). The Hsp 70/Hsp 90 chaperone 
system is essential in preventing protein aggregation by binding, folding or refolding of 
nascent or misfolded proteins (Liang and MacRae 1997; Kanelakis, Murphy et al. 2000; 
Beck and Nassal 2003).  
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A considerably large portion of the nascent proteins will fail during the folding process 
(Goeckeler and Brodsky 2010). Those failed proteins of folding intermediates are 
speculated to be degraded by proteasome activity including ER-associated ERAD 
(Meusser, Hirsch et al. 2005). Accumulation of unfold proteins triggers unfold protein 
stress response or aggregate formation in cells (de Almeida, Picarote et al. 2007; 
Nunziante, Ackermann et al. 2011). Expression of exogenous, mutated and unusual 
proteins, cellular injury, and genetic deficiencies are common reasons for aggregate 
formation. Protein aggregates are generally refractory to proteolysis but eventually are 
retrodegradely transported along microtubules to the juxtanuclear aggresome caged with 
vimentin filaments (Tanaka, Kim et al. 2004). We have demonstrated that HIF-1 is 
under the surveillance of the ER associated protein quality control system where OS-9 
directly interacts with HIF-1in ER-derived vesicles and promotes its degradation by the 
proteasome. This study indicates a novel mechanism that regulates HIF-1 stability and 
suggests that the ER protein quality control system appears to participate in the 
surveillance of nuclear proteins. 
The ubiquitination proteasome system (UPS) is the first and best characterized 
degradation pathway of HIF-1. The UPS encompasses protein ubiquitination and 
subsequent proteasome degradation (Hershko, Heller et al. 1983; Hershko and 
Ciechanover 1998). This process sequentially involves three enzymes: the ubiquitin 
activating enzyme (E1) with activates ubiquitin; the ubiquitin-conjugating enzyme (E2); 
and the ubiquitin ligase (E3) complexes that eventually attach ubiquitin to a protein 
substrate. The mammalian cell has a single E1, dozens of E2 and hundreds of E3 
complexes, reflecting well-controlled substrate specificity. The ubiqutination of HIF-1a 
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depends on functional E1 and VHL (E3). The final destination of ubiquitinated proteins 
are proteasomes which exist in both the cytosol and nuclei. Mammalian cells have two 
types of proteasomes, 20S and 26S proteasomes. The 26S proteasome consists of the core 
20S proteasome, and a 19S cap recognizes ubiquitinated proteins with high fidelity, 
ensuring the 26S proteasome specifically degrades ubiquitinated proteins, and the cap is 
needed to unfold and de-ubiquitinate the proteins, enabling their entery into the 
proteolytic chamber. The cap-less 20S porteasome is unable to degrade folded or 
polyubiquitinated proteins. We have demonstrated that two point mutations on E1 protein 
cause the instability of E1 protein under restrictive temperature which further leads to the 
inhibition of the ubiquitination process. This study validates an essential model cell line 
to study the ubitination-dependent and –independent degradation of proteins. 
The UPS system has been implicated in the degradation of important bioactive regulatory 
proteins, such as cell cycle regulators. It is also an important part in the ER-associated 
degradation of misfolded proteins (ERAD). Currently several proteasome inhibitors (PSIs) 
are used in clinical trials or research, including MG132, PS341, lactacystin, expoxomicin 
and eponemycin (Orlowski, Stinchcombe et al. 2002; Adams 2004; Ishii, Waxman et al. 
2007). These inhibitors specifically target the proteolytic activity of the 20S proteasome, 
but not the ubiquitination steps. Importantly, PSIs increase both total HIF-1 levels and 
HIF-1 association with HIF-responsive elements (HRE) of its target genes. However, an 
increase in the HIF-1 levels and its association with HRE caused by PSIs does not result 
in enhanced HIF activity (Kaluz, Kaluzova et al. 2006; Kaluz, Kaluzova et al. 2008). 
Conversely, PSIs are found to repress the expression of HIF target genes. 
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Nevertheless, 20S proteasome has been reported to degrade unfolded P53, ODC 
(ornithine decarboxyase) and P27 through the ubiquitin independent proteasome system 
(UIPS) (Nguyen, Gitig et al. 1999; Asher, Lotem et al. 2002; Kahana and Reiss 2005). 
Since these proteins are also substrates for 26S proteasome therefore for both UDP and 
UIP degradation. It is interesting to note that multiple pathways might account for the 
degradation of a specific protein. 
These findings from us and others suggest the involvement of an orchestrated quality 
control system (QCS) for HIF-1 which involves Hsp70/Hsp90, the ubiquitin 
proteasome system and the ER-associated protein quality control system. Further 
investigation of how these protein quality control systems talk to each other need to be 
addressed. What specific ER-quality control components, other than OS-9, are involved 
in the regulation of HIF-1? How does ER-quality control system recognize HIF-1? Is 
ER-quality control system also involved in the quality control of other nuclear proteins? 
Will tunicamycin or its derivatives inhibit hypoxic tumor growth in animal tumor models 
or even in the clinical studies? All these questions remain to be addressed by further 
studies.   
Taken together, our data indicate that an OS-9 participated ER function is involved in the 
UIP degradation of HIF-1 which may form part of the quality control system of HIF-1. 
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